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7AbstrAct
In Sweden, approximately 25000 patients suffer a cerebral infarction (stroke) annually. Stroke 
ranks as the third-leading cause of death, and is the leading cause of functional impairment. 
Carotid artery stenosis accounts for approximately 15% of all strokes and almost all of these 
are theoretically preventable. 
There are two conceptually different invasive methods used to treat carotid stenosis: carotid 
artery stenting (CAS) and carotid endarterectomy (CEA). There are various aspects of these 
treatments that remain to be evaluated in order to minimize the risks of poor outcome, namely: 
any differences in short-term and long-term outcomes after CEA or CAS, the potential risks of 
CAS early after a previous transient ischaemic attack (TIA)/stroke, and the methods to indicate 
the need of shunting during CEA. Furthermore, since data from randomised controlled trials 
(RCTs) are often from specialized high volume centres with selected patients, it is important to 
evaluate population-based results after CAS and CEA.
The overall aim of this thesis was to investigate aspects of invasive treatment of carotid artery 
stenosis, in particular the outcome following endovascular treatment (CAS), and the efficacy 
of near-infrared spectroscopy in predicting selective shunt use during CEA.
The outcome after endovascular treatment was investigated in three cohort studies (study I, 
II, and III). In study I, we analysed Swedish national short-term results of CAS and CEA and 
compared a high-volume centre with national results for CAS. In study II we evaluated the 
procedural risk of CAS, in relation to time from previous TIA /stroke. Study III assessed the 
long-term population-based outcomes after CAS as compared to CEA. In study IV, a multi-
centre diagnostic study, we evaluated the ability of near-infrared spectroscopy (NIRS) to pre-
dict cerebral ischaemia during CEA.
Study I was a retrospective single-centre review of all consecutive patients treated with CAS 
at Södersjukhuset between 2004-2011. These results were compared to data from the Swedish 
national registry for vascular surgery (Swedvasc), where data from all patients treated with 
CAS or CEA during the same period was extracted.  We found that the Swedish national results 
for CAS were inferior to CEA, but also that it was possible to achieve acceptable results with 
CAS in a high volume centre. During the study period 464 CAS procedures were performed in 
Sweden, with 208 of them performed at Södersjukhuset. The stroke and death rate at 30 days 
among patients in Sweden (Södersjukhuset excluded) was 7.4%. In Södersjukhuset, the stroke 
and death rate was 2.9%. The results for CAS on a national basis improved over time, the 
stroke and death rate during the first half of the period was 6.4%, compared to 3.6% in the sec-
ond part of the study period, which was probably due to the learning curve for the procedure. 
In study II, all CAS performed for symptomatic carotid stenosis between 2005-2014, were 
included in a retrospective analysis. Study II revealed that it was safe to perform CAS early 
(within 1 week), following a TIA/stroke. The stroke and death rate for patient treated within 7 
days from neurologic symptom was 4.1%, compared to 6.3% between day 8-14, 4.8% between 
day 15-28, and 3.6% between days 29-180. 
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The long-term results after CAS in Sweden were examined in study III. In this study, all pri-
mary CAS procedures registered in Swedvasc were included (all reoperations were excluded). 
We compared 409 CAS patients to a control group treated with CEA. The control group was 
matched with respect to known confounding factors. Postoperative stroke was identified by 
cross matching the cohort with the In-patient registry. Median follow-up time was 4.1 years, 
and follow-up data was almost complete. By using Cox regression, we found a substantial 
(59%) increased risk for late(>30 days) stroke or death for patients treated with CAS compared 
to CEA. This increased risk was mainly due to an increased risk of ipsilateral stroke during 
long-term follow-up. 
In study IV, we have shown that near-infrared spectroscopy has a high sensitivity and accept-
able specificity to predict cerebral ischemia during CEA. When a cut-off point of 9% relative 
decrease in regional SO2 during carotid clamping was chosen, the sensitivity for detecting 
cerebral ischemia was 95%, and the specificity 81%. This was clearly superior to the conven-
tional and widespread technique of measuring, “stump pressure”. 
In conclusion, the national population-based results for CAS were inferior to CEA, both short- 
and long-term. The short-term results after CAS in Sweden have improved over time, and 
acceptable results can be achieved in high volume centres. If CAS is performed due to symp-
tomatic stenosis it could be performed early after onset of neurologic symptoms.
Near-infrared spectroscopy is a reliable method for selective shunting during CEA and superior 
to stump pressure.
Keywords: carotid artery stenosis, carotid artery stenting, carotid endarterectomy,  
Near-infrared spectroscopy, shunting.
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(svensk sammanfattning)
Bakgrund
Slaganfall (stroke) är en av våra vanligaste folksjukdomar. Varje år drabbas cirka 25000 
svenskar av stroke. I Sverige är stroke den tredje vanligaste dödsorsaken och en ledande orsak 
till allvarliga handikapp. Närmare 15% av alla stroke orsakas av en förträngning av halspulså-
dern (karotisstenos), detta gör denna grupp särskilt intressant eftersom denna typ av stroke kan 
förebyggas med kirurgiska ingrepp. 
Karotisstenos är vanligen ett resultat av åderförkalkning och från denna förträngning kan ib-
land små fragment lossna och åka upp med blodet till hjärnan och därigenom orsaka en blod-
propp och stroke. Stora randomiserade studier har visat att kirurgisk behandling av karotisste-
nos minskar risken för stroke jämfört med bästa medicinska behandling. 
Det finns två principiellt olika kirurgiska metoder att behandla karotisstenos: endovaskulär 
stentbehandling, ofta kallat ”ballongvidgning” och öppen kirurgisk operation. Om någon av 
metoderna är överlägsen den andra är oklart. 
Vid öppen kirurgisk behandling av karotisstenos stängs blodflödet till ena hjärnhalvan av under 
en del av ingreppet. Hos många patienter räcker blodtillförseln från andra hjärnhalvans blod-
kärl för att försörja hela hjärnan med blod. Hos andra räcker inte detta, utan blodet behöver 
ledas förbi operationsområdet i en tunn slang (shunt) upp till hjärnan under den period som 
blodflödet är avstängt. Att använda shunt gör att operationen blir tekniskt mer komplicerad 
varför många önskar använda shunt endast när det verkligen behövs.  Det finns olika metoder 
för att avgöra vilka patienter som verkligen utvecklar syrebrist i hjärnan, men de hittills beprö-
vade metoderna har alla sina tillkortakommanden. En ny och praktiskt enkel metod kan genom 
att två elektroder tejpas på pannan mäta syremättnaden i hjärnan, denna kallas near-infrared 
spectroscopy, NIRS. 
Även om kirurgisk behandling av karotisstenos är ett välstuderat område så finns fortfarande 
kunskapsluckor som har avgörande klinisk betydelse för resultaten av den kirurgiska behand-
lingen.
Den övergripande målsättningen med avhandlingsarbetet var att belysa några av dessa kun-
skapsluckor och besvara frågorna:1. Hur ser de svenska resultaten ut efter stentbehandling eller öppen operation av  
karotisstenos, på kort sikt och på lång sikt? 2. Hur nära inpå ett slaganfall eller TIA kan man behandla karotisstenos med  
endovaskulär stentbehandling? 3. Hur pålitligt är NIRS för att förutsäga vilka patienter som utvecklar syrebrist och  
därmed behöver shunt under öppen operation av karotisstenos?
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Den första frågan studerades i två retrospektiva kohortstudier (arbete I och arbete III).  
I arbete I analyserades resultaten av 464 stentbehandlingar utförda i Sverige mellan år 2004-
2011, 208 av dessa var utförda på Södersjukhuset. Vi fann att de nationella resultaten vid 
stentbehandling var sämre än vid öppen kirurgisk behandling för karotisstenos på kort sikt, 
men att acceptabla resultat kunde uppnås på en enhet med stor volym. I Sverige (exklusive 
Södersjukhuset) drabbades 7.4% av patienterna av stroke eller död inom 30 dagar från ope-
rationen. I jämförelse drabbades 2.9% av patienterna behandlade på Södersjukhuset av stroke 
eller död. Vi fann att de nationella resultaten förbättrades under studietiden, sannolikt en effekt 
av en inlärningskurva.
I arbete III undersöktes resultaten efter samtliga karotisstentbehandlingar utförda i Sverige 
mellan 2005-2012 (reoperationer var exkluderade). Som jämförelse användes öppet opererade 
patienter som var matchade med avseende på kända riskfaktorer för stroke och död. Patienterna 
följdes i medeltal 4.1 år. Vi fann att patienter behandlade med stentning hade 59% ökad risk att 
drabbas av sen (mer än 30 dagar efter ingreppet) stroke eller död jämfört med öppet opererade. 
Den ökade risken berodde framförallt på en ökad risk för stroke på den behandlade sidan.
Den andra frågan studerades i en retrospektiv studie av stentbehandlade karotisstenoser och där 
resultaten av ingreppet delades upp i förhållande till hur lång tid som förflutit mellan operatio-
nen och den stroke eller TIA som var anledningen till ingreppet. Vi fann inte någon ökad risk 
med att behandla symptomgivande karotisstenos tidigt (inom en vecka) i anslutning till stroke 
eller TIA jämfört med att vänta längre tid till operation. 
Den tredje frågan studerades i en prospektiv multicenterstudie med 185 patienter inkluderade. 
Studien visade att om NIRS-syremättnaden sjunker med 9% i samband med avstängning av 
halspulsådern så bör man använda shunt vid ingreppet.  Med denna 9%-gräns för shuntning 
fann vi att NIRS har en sensitivitet på 95% och specificitet på 81% att detektera syrebrist i hjär-
nan. Detta var klart bättre än den konventionellt använda metoden ”stumptryck”. 
Sammanfattningsvis har detta avhandlingsprojekt visat att i Sverige är resultaten efter öppen 
operation av karotisstenos mycket bra. Stentbehandling av karotisstenos på nationell nivå har 
något ökade risker jämfört med öppen operation på kort sikt och på lång sikt. Resultaten efter 
stentbehanding har dock förbättrats över tid och kan vara acceptabla på sjukhus med stor vo-
lym och erfarenhet. Vid de fall då stentbehandling är att föredra framför öppen kirurgi behöver 
behandlingen inte fördröjas utan kan ske skyndsamt (inom en vecka efter tidigare TIA eller 
stroke). NIRS är en säker metod som kan rekommenderas för att besluta om shuntning under 
öppen operation av karotisstenos.
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AbbreviAtions
ACAS  Asymptomatic Carotid Atherosclerosis Study 
ACST  Asymptomatic Carotid Surgery Trial 
AMI  Acute myocardial infarction 
CAS  Carotid artery stenting 
CEA  Carotid endarterectomy 
CCA  Common carotid artery 
CREST  Carotid Revascularization vs Stenting Trial 
CI  Confidence interval 
ECST  European Carotid Surgery Trial 
EPD  Embolic protection device 
EVA-3S  Endarterectomy Versus Angioplasty in Patients With Symptomatic Severe   
 Carotid Stenosis 
GA  General anaesthesia 
ICA Internal carotid artery 
ICD International Classification of Disease 
ICSS  International Carotid Stenting Study 
IPR In patient registry 
IQR  Inter quartile range 
LA  Local anaesthesia 
MRI  Magnetic resonance imaging 
NASCET  North American Symptomatic Carotid Endarterectomy Trial 
NNT  Numbers needed to treat 
OR  Odds ratio 
P-value  Probability value 
RCT  Randomised controlled trial 
ROC curve  Receiver operating characteristic curve 
SD  Standard deviation 
SAPPHIRE  Stenting and Angioplasty with Protection in Patients at High Risk for End  
 arterectomy 
SP  stump pressure 
SPACE  Stent-Protected Angioplasty Versus Carotid Endarterectomy 
SVS  The Society for vascular surgery 
Swedvasc  Swedish national registry for vascular surgery 
TCD  Transcranial doppler 
TIA  Transient ischemic attack 
WHO  World Health Organization
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1 Aims of the thesis
The overall aim of the thesis was to investigate aspects of surgical treatment of carotid artery 
stenosis, in particular the outcome following endovascular treatment, and the efficacy of near-
infrared spectroscopy in predicting the need for a shunt during carotid clamping. 
Specific aims:
• To analyse short-term results of carotid artery stenting compared with carotid endar-
terectomy and compare a high-volume single centre with national results of carotid 
artery stenting (paper I).
• To evaluate the procedural risk of carotid artery stenting for symptomatic carotid 
stenosis in relation to the time from the qualifying neurological event (paper II).
• To assess the long-term outcomes of carotid artery stenting as compared to carotid 
endarterectomy (paper III).
• To evaluate the efficacy of near-infrared spectroscopy in predicting the need for a 
shunt during carotid clamping in patients undergoing carotid endarterectomy  
(paper IV). 
16
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2 bAckground
2.1 Introduction
Stroke –a widespread disease
In Sweden, there are approximately 25000 patients who suffer a cerebral infarction (stroke) 
annually.1 Stroke ranks as the third-leading cause of death in Sweden, after heart disease and 
cancer, and is a leading cause of functional impairment.2 3 In the last decades, stroke incidence 
rates have fallen in high-income countries, like Sweden, but increased in low- and middle –
income countries.4 In 2010, an estimated 16.9 million people worldwide had their first stroke 
event.5 Well known causal risk factors for stroke are; hypertension, hypercholesterolemia, ca-
rotid stenosis and atrial fibrillation; additional probable causes include cigarette smoking, dia-
betes mellitus and excessive alcohol use.6 Other factors that might increase the risk of stroke 
include; environmental air pollution, childhood health circumstances and fitness, high-risk diet 
and poor nutrition, physical inactivity, obesity, blood pressure variability, sleep-disordered 
breathing, chronic inflammation, chronic kidney disease, hormonal contraception, hormone 
replacement therapy, psychosocial stress, depression, job strain and long working hours.6
The reason for the decreased stroke rate in high-income countries is believed to be driven by 
a decline in smoking, better blood pressure control, and decreased serum cholesterol levels. 
The serum cholesterol levels started to decrease long before the widespread use of statins in 
high-income countries, indicating a dietary effect.4, 7 On top of the 25000 strokes per annum, 
approximately 10000 patients suffer a transient ischemic attack (TIA) yearly in Sweden. 
Carotid artery stenosis accounts for approximately 15% of all strokes8, and treatment of carotid 
stenosis can thereby reduce the number of strokes. 
Early experience of carotid endarterectomy (CEA) and carotid artery stenting (CAS)
The impact of carotid artery occlusion on neurologic symptoms has been known since Hip-
pocrates, but it was not until 1809 the British surgeon Sir Astley Cooper discussed the possibil-
ity of stroke after carotid ligation.9 Miller Fisher described the association of occlusion of the 
carotid artery and embolism to the brain and ischemic stroke.10 In 1953, Dr Michael DeBakey 
performed the first successful carotid endarterectomy9, but the first reported carotid endarterec-
tomy for symptomatic stenosis was published in 1954 by Eastcott, Pickering and Rob.11 These 
events led to a general understanding of the stroke protective benefits of the operation. During 
the 1980s treatment by means of CEAs increased rapidly worldwide.
Angioplasty of the internal carotid artery was described in 1967 with open gradual dilation 
for fibromuscular dysplasia.12 Mathias et al reported the first percutaneous angioplasty of the 
carotid artery in 19779, 13, and the first Carotid Artery Stenting (CAS), was performed by Ker-
ber at al in 1980.14 Ever since this first CAS, there has been a rapid development of different 
materials and devices to reduce the risk of distal embolization.
18
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The first evidence from randomised controlled trials of benefit for treating carotid artery 
stenosis surgically
In the 1980s, reports about inappropriateness of indication and unacceptably high complica-
tions rates led to a decline in the number of carotid operations performed.15, 16And there was a 
need for evidence from randomized controlled trials to justify the operation. These events led 
to two large randomized controlled trials were set up: North American Symptomatic Carotid 
Endarterectomy Trial (NASCET)17, and European Carotid Surgery Trial (ECST).18  These trials 
showed that CEA could reduce the risk of stroke and death in patients with recent neurologic 
symptoms caused by carotid artery stenosis. Additionally, Asymptomatic Carotid Atherosclero-
sis Study (ACAS)19 and Asymptomatic Carotid Surgery Trial (ACST)20 showed that CEA could 
reduce the risk of stroke for patients with asymptomatic carotid stenosis compared to medical 
therapy alone. These trials led to a rebound of surgical treatment of carotid artery stenosis. 
Ever since the publication of NASCET and ECST, carotid endarterectomy has been adopted as 
the standard treatment for symptomatic carotid artery stenosis. 
In Sweden, over the last 10 years, approximately 1000 carotid procedures are performed annu-
ally, aiming to reduce the number of strokes in the population. It is therefore relevant to analyse 
the results from the carotid procedures with the aim to minimise the complication rate of the 
procedures.  
2.2 Asymptomatic carotid artery stenosis
Carotid stenosis is a narrowing of the lumen of the carotid artery, usually caused by athero-
sclerosis. Most often this narrowing occurs at the division of the common carotid artery to the 
internal carotid artery (which supplies the brain with blood), and external carotid artery. 
Definition
Asymptomatic carotid artery stenosis includes patients with no history of neurologic symp-
toms related to the ipsilateral carotid territory, or those with symptoms > 180 days ago. Conse-
quently, patients with atypical or non-focal neurologic symptoms or vertebrobasilar symptoms 
are also considered “asymptomatic”. 
Prevalence
The prevalence of carotid stenosis increases with age. Before 70 years of age, the prevalence of 
moderate stenosis (≥50%) is 4.8% in men, and 2.2% in women as compared to 12.5% in men 
and 6.9% in women over 70 years.21, 22
Treatment for asymptomatic carotid artery stenosis
Two large-scale randomized trials, ACST-1 (Asymptomatic Carotid Surgery Trial-1) and ACAS 
(Asymptomatic Carotid Atherosclerosis Study) have demonstrated that CEA reduces the risk 
19
of having a stroke as compared to medical treatment alone.19, 20 Even later data, has proven a 
long-lasting stroke protective effect of CEA at 10 years.23 However, only 50-60 strokes per 
1000 CEAs will be prevented, thus approximately 95% of the patients will undergo an unnec-
essary intervention.24
The best treatment for asymptomatic carotid stenosis is controversial, and different strategies 
are proposed in different countries. Current SVS (society for vascular surgery) guidelines pro-
pose that asymptomatic patients with ≥60% stenosis should be considered for CEA provided 
that the patient has a 3 to 5 year life expectancy and perioperative stroke/death rates of less than 
3%.25 A systematic review of guidelines in different countries and regions identified several 
different strategies for asymptomatic carotid stenosis in different countries: best medical treat-
ment, CEA and/or CAS. 26
The patients in ACST-1 and ACAS were included in these trials in 1993-2003 and 1987-1993 
respectively. In more recent studies, the reported annual risk for ipsilateral stroke among non-
surgically treated patients with asymptomatic carotid stenosis has decreased significantly, and 
an annual stroke rate of less than 1-1.5% may be achieved with modern medical therapy. 27-30 
The main reason is that current best medical treatment is more effective than during the ACST-
1 and ACAS, including higher statin doses, better blood pressure control and more effective 
antithrombotic medication.
Identifying patients at high risk for stroke
There may be a subgroup of patients with asymptomatic stenosis who have a higher annual 
stroke risk than the average asymptomatic patient and therefore would benefit more from in-
tervention. In the ACSRS (Asymptomatic Carotid Stenosis and Risk of Stroke study), patients 
with previous TIA or stroke on the contralateral side had an increased risk, as well as patients 
with stenosis progression.30, 31 Large plaque area, microulcers, microembolization on TCD and 
silent infarctions have all been reported to increase the risk of stroke. 24, 32-34, 195 Echolucent, 
“soft” plaques on duplex has been associated to increased stroke risk.35, 194, 195 Also, intra-plaque 
haemorrhages on MRI have been reported to be associated with ischemic stroke 36, 37  There is, 
unfortunately, no established “risk score” for asymptomatic carotid stenosis.
Discrepancies between regions
Due to these uncertainties regarding asymptomatic carotid stenosis, other factors, such as eco-
nomical incentives can play a role in the choice of treatment. In the United States, more than 
90% of the carotid procedures (both CEA and CAS) were performed for asymptomatic steno-
sis, compared to 0% in Denmark in 2015.38-40 In Sweden, the proportion of carotid procedures 
for asymptomatic stenosis has decreased significantly the last 10 years; 28% in 2006 compared 
to 8.9% in 2015.38 
2.3 Symptomatic carotid artery stenosis
The World Health Organization’s definition of stroke is “rapidly developing clinical signs 
of focal (or global) disturbance of cerebral function, lasting more than 24 hours or leading to 
death, with no apparent cause other than that of vascular origin.”41 Since this definition was in-
troduced, new techniques of diagnoses and treatment such as MRI (magnetic resonance imag-
Background
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ing) and thrombolysis, have become widespread. The American Heart Association/American 
Stroke Association have proposed a new definition, in which the term stroke should be more 
broadly used and “include pathological, imaging, and/or other objective evidence of cerebral, 
spinal cord, or retinal focal ischemic injury in a defined vascular distribution or clinical evi-
dence of cerebral, spinal cord, or retinal focal ischemic injury based on symptoms persisting ≥ 
24 hours or until death, and with other aetiologies excluded”.42 To be able to compare outcome 
in different studies, it is important to use the same definitions of outcome. In reporting stan-
dards for carotid surgery, stroke is defined as a cerebral infarction that manifests as a sudden 
onset of focal neurological deficits that persist for more than 24 hours. In instances where a 
new cerebral infarction is demonstrated on MRI or DT, the occurrence of stroke should be 
documented even if the symptoms lasted < 24 hours.43
Transient ischemic attack (TIA) has several different definitions in use. Often, the definition 
of TIA is a sudden onset of focal neurological symptoms with duration of up to 24 hours, with 
total resolution or return to baseline, and with no image evidence of infarction. 44 2, 6, 43
Amaurosis fugax used to be defined after pathoetiology: embolic (type I), hypoperfusion (type 
II), angiospasm (type III) and unknown (type IV).45 It has been redefined as to transient monoc-
ular visual loss attributed to ischemia or vascular insufficiency. Typically, the patients describe 
rapid progression of visual impairment that progress over seconds or a few minutes. The loss 
of vision usually begins in the upper visual field as a “curtain phenomenon”.46
Symptomatic patients
Patients with carotid stenosis should be considered symptomatic if: they have a history of 
contralateral symptoms of TIA/stroke, or amaurosis fugax involving the ipsilateral carotid ter-
ritory. For practical reasons, and due to the fact that the risk of new neurological symptoms 
decreases with time after the initial symptoms, only patients with symptoms within 180 days 
are considered symptomatic.43
Stroke can be classified into different subgroups depending on severity of the functional im-
pairment. Modified Rankin scale (mRS) is a simple method often used for this purpose. Often, 
the term major stroke or disabling stroke is considered for patients with mRS≥2. 
Modified Rankin Scale 
0-No symptoms
1-No significant disability, despite symptoms; able to perform all usual duties and activties. 
2-Slight disability; unable to perform all previous activities but able to look after own affairs.
3-Moderate disability; requires some help, but able to walk independently.
4-Moderate severely disability; unable to walk without assistance and unable to attend to own body needs 
without assistance.
5-Severe disability; bedridden, incontinent and requires constant nursing care and atttion.
6-Death
21
The National Institutes of Health Stroke Scale, or NIHSS 
The NIHSS is another widely used tool to evaluate and quantify the severity of stroke. NIHSS 
early after stroke onset can be used to predict final outcome after a stroke.47 A baseline NIHSS 
≤ 3 at admission is associated with good long-term outcome, and has been proposed to be used 
for “minor stroke”.48
NIHSS49
Instruction Scale definition Score
1a. Level of consciousness 
(LOC)
0 = Alert, 1 = Not alert; but arousable by minor stimulation, 
2 = Not alert; requires repeated stimulation to attend, 3 = Re-
sponds only with reflex motor or autonomic effects or totally 
unresponsive
1b. LOC questions - The pa-
tient is asked the month and his/
her age
0 = Both questions correctly, 1 = One question correctly, 2 = 
Neither question correctly.
1c. LOC commands - The pa-
tient is asked to open and close 
the eyes and grip and release
0 = Performs both tasks correctly, 1 = Performs one task cor-
rectly, 2 = Performs neither task correctly.
2. Best gaze - Only horizontal 
eye movements will be tested
0 = Normal, 1 = Partial gaze palsy; gaze is abnormal in one 
or both eyes, 2 = Forced deviation, or total gaze paresis not 
overcome by the oculocephalic manoeuvre.
3. Visual - upper and lower 
quadrants are tested 
0 = No visual loss, 1 = Partial hemianopia, 2 = Complete 
hemianopia, 3 = Bilateral hemianopia
4. Facial palsy - show teeth or 
raise eyebrows and close eyes
0 = Normal symmetrical movements, 1 = Minor paralysis, 2 
= Partial paralysis (total or near-total paralysis of lowerface), 
3 = Complete paralysis of one or both sides 
5. Motor arm - The limb is 
placed in the appropriate posi-
tion: extend the arms (palms 
down) 90 degrees (if sitting) 
0 = No drift; limb holds for full 10 seconds, 1 = Drift; limb 
holds 90 degrees, but drifts down before full 10 seconds, 2 = 
Some effort against gravity, 3 = No effort against gravity, 4 = 
No movement, UN = Amputation or joint fusion, explain: 
6. Motor leg - hold the leg at 30 
degrees
0 = No drift; leg holds position for full 5 seconds, 1 = Drift; 
leg falls by the end of the 5-second period, 2 = Some effort 
against gravity, 3 = No effort against gravity, 4 = No move-
ment. UN = Amputation or joint fusion, explain: 
7. Limb ataxia - The finger-
nose-finger and heel-shin tests 
are performed on both sides
0 = Absent. 1 = Present in one limb. 2 = Present in two limbs. 
UN = Amputation or joint fusion, explain
8. Sensory - Sensation or gri-
mace to pinprick when tested,
0 = Normal; no sensory loss, 1 = Mild-to-moderate sensory 
loss, 2 = Severe to total sensory loss; patient is not aware of 
being touched in the face, arm, and leg.
9. Best language - the patient is 
asked to describe what is hap-
pening in the attached picture
0 = No aphasia; normal, 1 = Mild-to-moderate aphasia; some 
obvious loss of fluency or facility of comprehension, without 
significant limitation on ideas expressed or form of expres-
sion, 2 = Severe aphasia; all communication is through frag-
mentary expression, 3 = Mute, global aphasia 
10. Dysarthria - asking patient 
to read or repeat words from the 
attached list.
0 = Normal. 1 = Mild-to-moderate dysarthria, 2 = Severe dys-
arthria; patient’s speech is so slurred as to be unintelligible, or 
is mute. UN = Intubated or other physical barrier.
11. Extinction and inattention 
(formerly neglect)
0 = No abnormality, 1 = Visual, tactile, auditory, spatial, or 
personal inattention, 2 = Profound hemi-inattention or extinc-
tion to more than one modality; does not recognize own hand 
or orients to only one side of space.
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Treatment for symptomatic carotid artery stenosis
In 1991, randomization within NASCET was halted for patients with severe stenosis (70-99%) 
due to a substantial benefit in major outcome (stroke and death) at 2 years for the surgical 
group.50 Absolute risk reduction of ipsilateral stroke was 16.5%, with a relative risk reduction 
of 65%. Similar results were reported in the interim results of ECST.51 
In 1998, the final results of ECST and NASCET were published. They concluded that there 
was a moderate effect of carotid endarterectomy in symptomatic patients with moder-
ate stenosis, and a substantial effect in patients with symptomatic severe stenosis.17, 18 
2.4 Carotid endarterectomy and carotid artery stenting
Imaging before intervention
The degree of ICA stenosis can be measured by different modalities. The gold standard has 
been selective digital subtraction angiography (DSA), which was the modality used in the 
randomized trials, NASCET and ECST. These two trials measured the degree of stenosis on 
different locations on the arteries and there are clinically important disparities between them. 
Thus, it is important to explicit describe what method is used for a certain degree of stenosis, 
“% stenosis according to NASCET” and “% stenosis according to ECST”. It is possible to con-
vert measurements made by one method to the other using a simple equation.52 
Today, DSA is rarely used for stenosis grading, and has largely been replaced by other modali-
ties: duplex ultrasound, CT angiography, or MR angiography which all have high sensitivity 
and specificity for detection of severe carotid artery disease.53, 54, 55 
Jogestrand et al showed that peak systolic velocity is the most reliable parameter to describe 
degree of stenosis for duplex ultrasound.56 They also demonstrated the relevance of using cor-
rect doppler angle and that different peak velocity criteria should be used at different doppler 
angles.54  
Many patients undergo duplex ultrasound for screening, and CT/MR angiography, which can 
give additional information about the intracerebral circulation, and characterization of the 
plaque as discussed earlier. CT/MR angiography also gives information about the aortic arch 
and in-flow stenosis.
Surgical technique of CEA
The operation begins with a skin incision parallel to the sternocleidomastoid muscle, centred 
over the carotid bifurcation, through the platysma and the sternocleidomastoid muscle is re-
tracted laterally. The facial vein is ligated. The jugular vein is exposed and the carotid sheath 
is opened on the anterior border of the vein, which is retracted laterally. The common carotid 
artery is then dissected free and behind the artery, the vagus nerve is usually exposed. The 
dissection is continued upward to isolate the external carotid artery. The distal internal carotid 
artery is mobilized where the vessel is normal. The digastric muscle can be divided if neces-
sary. Mobilization of the carotid bifurcation should be minimized to avoid embolization. The 
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ansa cervicalis, a branch of the hypoglossal nerve, may be divided. Attention must be paid to 
the hypoglossal nerve and traction of the cranial nerve should be gentle to avoid injuries on the 
marginal mandibular branch of the facial nerve.
Anaesthetic- and shunt perspectives are discussed in section 2.6, shunting during carotid end-
arterectomy.
Type of endarterectomy
In eversion CEA the internal carotid artery is transected through the bifurcation. The adventitia 
is rolled back and the plaque can be removed and the internal carotid artery reimplanted. 
In conventional CEA a longitudinal arteriotomy is performed and the plaque is then removed. 
The arteriotomy should be closed with a patch, synthetic patches are superior to vein patches.57, 58
Eversion CEA has some potential advantages over conventional CEA, namely: fewer reste-
noses, shorter operation time and no synthetic material, but the perioperative results between 
eversion CEA and conventional CEA are equal.59, 60
Present technique of CAS
After access via a femoral puncture, a long catheter is introduced in the common carotid artery. 
An arteriogram is obtained in an anterior oblique angulation. A stiff guidewire is placed in the 
external carotid artery and a sheath is placed in the common carotid artery. The next step is to 
advance a protection device: either positioning a filter distally to the lesion in the internal ca-
rotid artery, or to reverse the flow, by occluding the external carotid artery and common carotid 
artery with balloons. A self-expandable stent with or without predilation is placed across the 
lesion and deployed. After balloon dilatation, a completion angiogram is performed.
Protection device
No large scale randomized controlled trial has investigated the efficacy of embolic protection 
devices, but cohort studies support the use of a protection device.61, 62 There are two principally 
different protection devices on the market: proximal occlusion, and distal filter. Theoretically, 
proximal occlusion has some advantages over distal filters, since it reverses the flow over the 
stenosis and redirects embolic particles; also, the stenosis is never crossed without protection. 
There is some support that filters create more micro emboli than proximal occlusion, but no 
study has showed any difference in stroke frequency.63-65 A combination of distal filter and 
proximal occlusion might be even more effective in reducing distal embolization than each 
method used separately.66, 67
Transcervical approach
Almost 10 % of all perioperative strokes with CAS are on the contralateral side, indicating that 
avoiding manipulation of the aortic arch could reduce the stroke rate. One way to avoid the 
problem with the arch is the direct cervical approach, which has reported excellent results for 
stenting. 68, 69 In 2015, the ROADSTER trial (Reverse flow used during carotid artery stenting 
procedure) presented the lowest perioperative stroke rate ever reported after CAS in a prospec-
tive multicentre trial, 1.4%.70 In the ROADSTER trial, the common carotid artery was exposed 
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through a small incision and the intervention was performed directly through the common 
carotid artery, and a reversed flow system was used as an embolic protection device.  
New stents and materials
Microembolisation and trapped/prolapse debris and plaque through and within the struts of the 
stents are believed to be the major causes of postoperative stroke. To manage this, a closed cell 
design has been used.71 In closed cell design there are bridges between every cell in the stent so 
that the struts cannot penetrate the intima, but this has the disadvantage that it makes the stent 
more rigid than open designed stents. In a small RCT with embolization detected by TCD as 
the endpoint, the authors could not find any difference between open- and closed cell design.72 
A new generation of stents has been developed with a double layer of mesh to reduce the inter-
stices in the cells, and thereby deal with the protruding plaque, the so called mesh-stents.73, 74 
These stents have showed promising results in the CLEAR-ROAD study, with a stroke/death/
AMI rate of 2.1% at 30 days.75
Intervention for symptomatic carotid stenosis
After the introduction of CAS in the 1980s, several RCTs have compared the efficacy of CAS 
and CEA.
As demonstrated in table 1, the rate of stroke and death at 30 days was lower with carotid end-
arterectomy than carotid artery stenting. This was also the conclusion of a systematic review.76 
However this excessive risk seems to be most pronounced in elderly patients. An analysis of 
pooled data from EVA-3S, SPACE and ICSS showed that the risk of perioperative stroke or 
death from stenting were similar to that from CEA in patients younger than 70 years.77
Paraskevas et al., analysed and compared the results for CEA and CAS reported from regis-
tries, and found that stroke and death rates were significantly higher after CAS than after CEA, 
and that the results have not really improved over time, which would have otherwise been 
expected from improved experience and the development of a new technique.78
Table 1. Major randomized controlled trials comparing short-term outcome after 
CEA and CAS.
* Hazard Ratio 
† 120 day follow up 
# Includes postprocedural ipsilateral stroke
Study No  Patients
Symptomatic 
Patients
30 d stroke / 
death  
CAS (%)
30 d stroke / 
death  
CEA (%)
OR stroke/death 
CAS vs CEA 
(95% CI)
SAPPHIRE 
200479
334 96 5.5 8.4 Non-inferiority
EVA-3S 
200680
527 527 9.6 3.9 2.5 (1.2-5.1)
SPACE 
200681
1214 1214 7.68 6.51 1.19 (0.75-1.92)
ICSS 2010†82 1713 1713 8.5 4.7 1.86 (1.26-2.74)*
CREST 
2010#83
2502 1321 4.4 2.3 1.90 (1.21-2.98)*
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Intervention for asymptomatic stenosis
The ACT I trial had a 3:1 allocation ratio with 1089 CAS patients and 364 patients undergoing 
endarterectomy for asymptomatic stenosis. At 30-day follow-up, there was a non-significant 
difference for stroke or death: 2.9% in the CAS group, and 1.7% in the CEA group.84 
Although the CREST trial was not powered to identify differences among patients with as-
ymptomatic stenosis, CEA and CAS, both had low perioperative stroke or death rates with no 
significant difference between the methods, CAS 2.5% versus CEA 1.4%, (p = 0.15).83 
The on-going ACST-2 trial, aiming to randomize 5000 patients, is comparing CAS and CEA 
for asymptomatic carotid stenosis. An interim report from 691 randomized patients within this 
trial showed a 30-day stroke rate of 2.9% for all patients.85 
Thus, among asymptomatic patients, it seems to be more important to identify who should be 
intervened rather than which method should be chosen.
Long-term outcome after CAS and CEA
Stenting of the arteries in the lower limb have been associated with more occlusions and reste-
noses than after endarterectomy, and one concern has been that CAS might be associated with 
more restenoses and subsequent strokes, than CEA. The CAVATAS study (Carotid and Verte-
bral Artery Transluminal Angioplasty), reported a 31% risk of restenosis at 5 years after CAS 
compared with 10% after CEA.86 Also EVA-3S and SPACE studies reported higher incidence 
of restenosis in the stented group than in the CEA group (12% vs 5% at 3 years and 11% vs 5% 
at 2 years respectively).87, 88 In contrast, in CREST and ICSS there was no difference in rate of 
restenosis between CAS and CEA at long-term follow up.89-91
The CREST, ICSS and EVA-3S trials have reported long term outcomes: in the CREST trial 
there was no difference in stroke rate in the postprocedural period.89 In the ICSS, there were 
more strokes after 30 days in the stented group as compared to the endarterectomy group (HR 
1.53, 95% CI 1.02-2.31), but no difference between the groups with respect to postprocedural 
ipsilateral stroke.91 In EVA-3S there were similar rates of ipsilateral stroke after the periproce-
dural period.92 
The ACT-1 trial with patients treated for asymptomatic carotid artery stenosis found no differ-
ences between CAS and CEA in target lesion revascularisation, non-procedure ipsilateral or 
any stroke, and survival up to five years after intervention.84
The randomised controlled trials show little or no difference between CEA and CAS after 
the periprocedural period. Nevertheless, participating units are often specialized high volume 
units, and patients within these trials are highly selected, and there is a need for good quality 
data cohort studies to compare CEA and CAS in a real world setting.
Primary CAS in Sweden
In 2004, the results from the SAPPHIRE (Stenting and Angioplasty with Protection in Patients 
at High Risk for Endarterectomy) were published. This trial compared patients with elevated 
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surgical risk, based on cardio-pulmonary comorbidity, stenosis following previous endarter-
ectomy or irradiation, or contralateral carotid occlusion. The results of this trial showed non-
inferiority for treatment with CAS with respect to stroke or death at 30 days or ipsilateral 
stroke in the first year of treatment.79 After the publication of SAPPHIRE, there was growing 
enthusiasm for stenting, and in Sweden the number of CAS performed increased rapidly. A few 
years later, after the publication of EVA-3 S, CREST and ICSS, which showed an increased risk 
with CAS for symptomatic patients, combined with a more restrictive approach to treatment 
of asymptomatic stenosis, the number of CAS in Sweden has declined dramatically. In 2015, 
stenting accounted for only 3 % of all primary carotid procedures.38 Figure 1 illustrates the rise 
and fall of CAS in Sweden and the adoption to the results of the RCTs. 
Nevertheless, CAS still has an important role in selected cases, and is often used for treating 
restenosis, after radiotherapy, and is the treatment of choice for patients with a contralateral 
recurrent laryngeal nerve paresis.
Figure 1. The rise and fall of primary CAS in Sweden. 
2.5 Timing of carotid intervention 
– The time relation between symptoms and intervention.
Patients with carotid stenosis who have suffered a TIA or minor stroke are at high risk of hav-
ing a recurrent stroke, up to 15% the first week,93-97 although recent Swedish literature have 
reported a lower risk of recurrent stroke (2-8% within 1 week).98, 99 A declined recurrent stroke 
rate has also been reported for all TIA patients.100 The declined recurrent stroke rate might be 
attributable to better medical treatment.101, 102 Nevertheless, in symptomatic patients, a large 
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proportion of the recurrent strokes that occur after TIA, occur within the first 48 hours, and the 
majority of the recurrent strokes occur within a week.96, 98, 103-105 Patients with a stroke due to 
large artery atherosclerosis (thus including ICA) are at higher risk of having recurrent symp-
toms, as compared to stroke due to small vessel atherosclerosis or cardio-embolic strokes.8, 106 
In Sweden, in 2015, 19.2% of all patients treated for symptomatic carotid stenosis had new 
neurologic symptoms after the alarm symptom, and half of them were within 3 days.38 In the 
light of this, carotid intervention should be performed as soon as possible after a neurologic 
event. 
Is there a risk of early CEA?
The early experience of CEA described conversion of ischemic infarcts to haemorrhagic strokes 
if CEA was performed shortly after a neurologic event, and most surgeons waited at least 4-6 
weeks between presentation of symptoms and surgery.107-109
 In 2004, Rothwell et al. published pooled data from the large randomized trials, and showed 
that the numbers needed to treat (i.e. how many patients needs to be treated to prevent one 
stroke) was five for those randomized within 2 weeks after their last ischemic event, compared 
to 125 for patients randomized after more than 12 weeks.110 In the current recommendations 
from the European Society of Vascular Surgery guidelines symptomatic patients should un-
dergo treatment, preferably within 14 days of onset of symptoms.111 
Rockman et al. reported in 2006, that early (< 4 weeks) endarterectomy was associated with 
poorer outcome.112 These findings were supported by the Swedish study from Strömberg et al. 
who found an 11.5% stroke or death risk in patients operated on within 48 hours from onset of 
alarm symptom.113 In contrast, two recent studies could not support that the time interval after 
index event influenced the perioperative stroke or death rate.114, 115 
Cerebral infarcts larger than 4000 mm3, and stroke in evolution have been reported with poorer 
outcome in the acute setting.116-118 In conclusion, a possible higher perioperative stroke risk 
with early CEA is counterbalanced by a much higher stroke preventive effect, supporting early 
intervention in most cases. 
Early CAS
There is a concern of performing CAS early after the onset of neurologic symptoms, since one 
could suspect that passing a fresh thrombus with a guide wire would increase the risk of distal 
embolization and perioperative stroke. Furthermore, the potential advantage of proximal oc-
clusion device compared to distal filter is theoretically more pronounced for unstable plaques 
as compared to more calcified lesions.
The available data regarding risk with CAS, stratified for timing after onset of symptoms, is 
limited. The CAPTURE registry reported an increased rate of stroke or death when CAS was 
performed within 2 weeks of symptoms compared to after 2 weeks. Table 2 summarizes the 
published data so far. 
Clearly, there is a knowledge gap whether it is safe to perform CAS urgently, and what protec-
tion device should be used in this acute setting.
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Table 2.  Thirty-day stroke or death rate after CAS stratified for delay from index symptom.
*0-7 days 
†0-14 days 
‡0-13 days 
#14-180 days 
**Only patients with TIA included
Trends in Sweden
There is a clear trend in Sweden, whereby patients are being operated closer to alarm symptom. 
This is illustrated in figure 2 and figure 3 for the period 2008 to 2015, respectively (data from 
Swedvasc).38
time to cas
0 to 2 days 3 to 7 days 8 to 14 days 15 to 180 days
Wach, MM et al 
2013119 5/70 (7.1%) 4/88 (4.5%) 1/36(2.8%) 0/27 (0%)
Rantner, B et al 
2013120 13/138 (9.4%)* 19/234 (8.1%) 78/1062 (7.3%)
Topakian, R et al 
2007121 6/23 (26%)† 1/54 (1.9%)
Gröschel, K et al 
2008122 10/142 (7.0%)‡ 17/178 (10.0%)#
Setacci, C et al 
2010**123  1/26 (3.8%)
Figure 2. Decreasing time from alarm symp-
tom to intervention over the past 8 years. 
Data from Swedvasc.
Figure 3.  The proportion of patients oper-
ated within the recommended 14 days from 
alarm symptom has increased the last 8 
years. Data from Swedvasc.
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Intervention after thrombolysis
An increasing proportion of stroke patients are receiving thrombolytic therapy as acute treat-
ment for stroke. Some of them will be considered for carotid intervention and the proportion of 
patients undergoing carotid intervention after thrombolytic therapy in Sweden has increased, 
see figure 4. Several small cohort studies have reported that CAS and CEA could be performed 
early (< 14 days) after thrombolytic therapy without increased risk of perioperative stroke or 
death.124-126 127 It is unclear whether there is an increased risk of intracranial haemorrhage with 
intervention within the first 72 hours, but a recently published study indicates that it might be 
safe to treat the carotid stenosis even urgently (< 12 hours) after thrombolysis.126, 128 
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Figure 4. Carotid intervention after thrombolytic therapy has increased in recent years.  
Data from Swedvasc.
2.6 Shunting during carotid endarterectomy 
Why use shunt during CEA?
A shunt is a thin tube that can lead blood from the common carotid artery and back into healthy 
internal carotid artery distal to the plaque during the endarterectomy. Most of the strokes that 
occur during/after CEA are ischaemic and some may be caused by the temporary interruption 
of blood flow during the procedure when the common carotid artery is clamped. To restore the 
circulation to the brain an intraluminal shunt can be used during the operation, and this may 
reduce the perioperative stroke risk. When carotid endarterectomies are performed under lo-
cal anaesthesia (LA), 7-16% of patients develop neurological deficit during carotid clamping, 
due to insufficient collateral blood flow.129-134 Under such circumstances, most surgeons prefer 
using a shunt to restore blood flow. More controversial is shunting in CEA under general an-
aesthesia (GA).
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Selective or routine shunting
Shunt placement can be technically difficult and limits the exposure of the operation field. 
Additionally, shunting has potential risks such as; artery dissection, plaque embolization, air 
embolism, and shunt thrombosis.135, 136 On the contrary, in a shunt-all policy, the surgeons be-
come more familiar with the practice, minimizing technical problems and the endarterectomy 
can be carried out without stress. It has not been proven which is best, a shunt-all policy, se-
lective shunting, or non-shunting. Only a few randomized controlled trials have compared the 
use of selective and routine shunting, and no one has demonstrated any significant differences 
in patient related outcomes.137, 138 Several large clinical trials have demonstrated excellent re-
sults with routine shunting. 139-141 In contrast, excellent results have also been reported from 
centre using a no-shunt policy.142-144 All these results have led to substantial difference in shunt 
policy between countries and units.145 In Sweden most units use selective shunting (i.e. based 
on symptoms (LA) or indirect measures of cerebral ischemia (GA)), and in 2015, 31 % of the 
patients treated with carotid endarterectomy were performed using a shunt.38
Figure 5. Use of shunt (Pruitt-Inahara® (LeMaitre, Burlington, Massachusetts, USA)) 
during CEA.
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Anaesthesia during CEA
The debate whether to perform CEA under LA or GA is on-going. Evidence is lacking to favour 
either of the methods. The randomized controlled GALA trial (GA vs. LA) presented similar 
perioperative risks of stroke and death after CEA.134 LA has some possible advantages. Patients 
operated under LA are in general shunted less frequent than patients operated under GA (14% 
versus 43%).146 In the CREST trial, patients operated under LA had similar rate of myocardial 
infarctions as patients undergoing CAS, whereas patients operated under GA were more likely 
to have a postoperative myocardial infarction.147.  In contrast, in the GALA trial, there was no 
difference in rate of myocardial infarctions between patients operated under LA and GA.134 
A Cochrane analysis reported a trend towards lower 30-day mortality in the group operated 
under LA, but no statistical significance in major outcomes.146 However, for CEA done in LA 
the patient should be alert enough to do awake neurological testing during carotid clamping, 
and occasionally, the administration of local anaesthesia could affect deeper structures (such 
as intravasal injection, nerve damages), and cause a haematoma.148  GA has the advantage of a 
perfectly still operation field, and no problems with patient discomfort. Other potential advan-
tages with LA include avoiding of intraoperative hypotension and postoperative hypertension 
with the need of vasoactive medication. To summarize, since major outcomes between GA 
and LA do not differ, the type of anaesthesia chosen (local or general) should be based on the 
preference of the surgeon and the comfort of the patient. 
Methods to predict cerebral ischemia
Less than one out of five patients require a shunt during CEA under LA. Consequently, in a 
shunt-all policy more than 80% of the patients are shunted unnecessarily. In the GALA trial, 
43% of patients operated under general anaesthesia were shunted as compared to 14% under 
local anaesthesia (in the latter group, only 8.7% were shunted due to neurological symptoms, 
the others due to other reasons). To reduce the number of shunts in patients operated in GA, 
various methods have been used to predict cerebral ischemia during carotid clamping, but no 
study has identified a perfect method. 
Stump pressure 
The theory behind stump pressure is that the back bleeding from the internal carotid artery var-
ies with the adequacy of the collateral circulation and that this back bleeding can be quantified 
by measuring the back pressure of the internal carotid artery, distal to an occluding clamp. This 
is called the stump pressure, and is widely used for predicting cerebral ischemia and thus to 
indicate shunt use. The cut-off pressure when shunting is mandated is debated, and different 
thresholds have been advocated. Some studies have reported stump pressure as mean arterial 
pressure, whilst others as systolic pressure. The method suffers from low specificity, but the 
reported sensitivity is relatively high. Still, 10-20% of the patients who  required a shunt due 
to neurologic deficit have had a stump pressure of more than 50 mmHg. 129, 132, 133, 137 Studies 
performed on stump pressure in awake patients are presented in table 3
Other methods used for predicting cerebral ischemia during carotid clamping are Electroen-
cephalogram (EEG), transcranial Doppler (TCD) and somatosensory evoked potentials (SSEP). 
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Near-infrared Spectroscopy
Near-infrared Spectroscopy (NIRS) is a relatively new method to detect and predict cerebral 
ischemia. NIRS is using the fact that the scalp and skull are relatively transparent to light in the 
near infrared spectrum (700-1000 nm), and that oxygenated and deoxygenated haemoglobin 
reflect light differently in this spectrum. NIRS enables continuous monitoring of changes in 
regional cerebral oxygenation (rSO2) in the frontal cortex. It is non-invasive, easy to use, and 
applicable in all patients. Compared to EEG and TCD, that require specialist technician ser-
vice, NIRS is more cost effective.133 NIRS has been proven to correlate to SP, EEG and TCD 
in patients operated under GA.149-154 
NIRS is increasingly being used in cardiothoracic surgery to monitor cerebral perfusion to 
reduce the risk of malpositioning of cannula, and to reduce postoperative stroke in patients 
undergoing cardiac surgery.155, 156
Several different NIRS devices are available commercially, but no specific device has been 
proven to detect cerebral ischemia more accurately than the other. All use similar technology, 
but differ in a number of properties. For instance, different devices have different cut off values 
for rSO2. Two of the most used new devices are Foresight-Elite® (CAS Medical Systems Inc., 
Branford, CT, USA) and INVOS 5100C® (Medtronic, Minneapolis, MN, USA). A compari-
son between the two showed that Foresight-Elite might have less extracranial contamination 
than INVOS 5100C, but the clinical significance of this remains unknown.157 
Little is known about the ability of NIRS to detect cerebral ischemia during carotid clamping. 
Only a few small studies of NIRS and CEA under local anaesthesia have been performed (see 
table 4). Thus, there is a need to analyse if NIRS has the ability to predict shunt need for units 
using selective shunting during carotid endarterectomy, to reduce the risk of ischemic induced 
perioperative strokes. 
Table 3. Major studies of stump pressure under local anaesthesia
Author (year) No. of carotid 
endarterectomies
Shunt  
requency
SP > 50 mmHg 
and neurologic 
symptoms 
SP < 50 mmHg Symptomatic 
patients
Moore et al 
 (1969)130 **
48 10% 0/48 = 0% 35/48 = 73% 42%
Evans et al 
(1985)131 *
134 9.7% 3/13 = 23% 40/121= 33% 68%
Calligaro et 
al(2005)129 *
474 7.2% 3/34 = 9% 139/474 = 29% 25% 
Hans et al  
(2007)132 **
314 10% 3/32 = 9% 98/314 = 31% 23% 
*Systolic SP 
**Mean SP
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Author (year) No. carotid 
endarterec-
tomies
Shunt 
frequency
PPV /NPV Sens/
spec(%)
Cut-off 
value
Device Symptomatic 
patients
ROC 
analysis-
AUC
Ali et al 
(2010)149 49 16% 86/95 75 / 97.5 >20 % Invos NA NA
Ritter et al 
(2010)133 81 11% 82/100 100 / 96 ≥19% Invos 4100 63% 0.986
Samra et al 
(2000)158 99 10% 33/97 80 / 82 >20 % Invos 3100 NA NA
Stilo et al 
(2012)159 100 5% NA/NA 60 / 25 20 % Invos 4100 40 % NA
Rigamonti et al 
(2004)154 50 5% NA/94 44 / 82 15 % Invos 4100 NA NA
Moritz et al 
(2007)160 48 17% NA/NA 83/83 20 % Invos 3100 50 % 0.905
Table 4. Major studies of NIRS and CEA under local anaesthesia
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3 PArticiPAnts And methods
3.1 Study design
The study designs of the four papers are summarized in table 5.  
Table 5. Study design
Study design Participants Data source Outcome
Study I Retrospective 
cohort study 
Södersjukhuset CAS 
n = 208,  
CEA n = 552 
National results  
CAS n = 258,  
CEA n = 6474
Local hospital 
quality register 
and Swedvasc
30-day outcome 
after CAS and CEA
Study II Retrospective 
cohort study
National results 
CAS n = 323
Swedvasc Perioperative outcome 
in relation to urgency 
of CAS
Study III Matched cohort 
study
National results 
CAS n = 409, 
CEA n = 748
Swedvasc and  
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3.1.1 Swedish National registry for Vascular Surgery, Swedvasc
The Swedvasc registry was created in 1987 and reached nationwide coverage by 1994. It cov-
ers all centres performing carotid endarterectomy and/or carotid artery stenting in the country. 
Swedvasc is web-based, and the data is registered locally at each center. Procedure data is re-
corded along with comorbidities, risk factors and demographic data. Follow up data at 30-days 
include morbidity, complications, and outcome. 
Swedvasc is connected to the Swedish National Population Registry, and the mortality data is 
therefore 100% accurate. In general, the data derived from Swedvasc is highly accurate. One 
validation of the registry for the period year 2000-2004 showed an external validity on carotid 
procedures of 93.4%.161 A more recent international validation of the registry for year 2012, 
showed an external validity (the carotid procedures registered in the hospital administrative 
data was compared to what was registered in Swedvasc) on carotid procedures of 98.8%, and 
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internal validity (data from hospital records was compared to what was registered in Swed-
vasc) of 97.4 %.162 In May 2008, an updated version (2.0) of the registry was launched. The 
new version included minor changes of some of the risk factor definitions (see below). 
3.1.2 In patient registry, IPR
The National Board of Health and Welfare register all in-hospital admissions. In Sweden, hardly 
any hospitals with in-patient care are private, which enables this registry to cover all in-patient 
health care provided in Sweden. Surgical procedures as well as diagnosis with ICD-10 codes 
are registered on a personal basis. Hospital reimbursement is based on registered diagnosis 
and surgical codes, which motivates the hospitals to do correct coding. The IPR was founded 
in 1964 when the National Board of Health and Welfare began collecting data on somatic in-
patient care in six Swedish counties. Today, the national coverage of the IPR is currently almost 
100%. The IPR has high validity, and the sensitivity for stroke diagnosis is about 95%.163 
3.1.3 Definitions
In study I, II, and III we used the current criteria available from Swedvasc for risk factors and 
comorbidity.
Symptomatic stenosis was defined as all ipsilateral artery events within 180 days prior to the 
intervention of a patient with carotid stenosis. Non-hemispheric, vertebrobasilar and atypical 
symptoms, as well as hemispheric carotid symptoms prior 180 days, were regarded as asymp-
tomatic.
Stroke within 30 days includes any new or worsened focal neurologic deficit lasting more than 
24 hours, and also intracerebral bleedings.
Alarm symptom = Qualifying event = Index symptom is the neurological symptom resulting in 
the patient presenting to health care.
Time to intervention is the time period between the alarm symptom/qualifying event/index 
symptom, until treatment.
Renal insufficiency if serum creatinine ≥150 μmol/L (≥130 μmol/L in study IV).
Hypertension if on antihypertensive medication 
Diabetes mellitus if treated with oral antidiabetics and/or insulin.
Pulmonary disease includes chronic obstructive pulmonary disease and asthma.
Heart risk is current heart failure, angina pectoris, or earlier acute myocardial infarction. In 
Swedvasc 1.0, but not in Swedvasc 2.0, atrial fibrillation was included in the definition.
Current smoker includes quitting within the last 4 weeks.
Smoking in study I includes quitting up to five years ago.
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High risk for CAS in study I was defined as two or more risk factors out of: age > 70 years, 
pulmonary disease and renal insufficiency. 
In study I. If a postoperative stenosis was > 50%, it was regarded to be a restenosis. A flow 
velocity of ≥ 1.5 m/s and a velocity quota for internal carotid artery/ common carotid artery of 
≥ 2.2 measured at a flow angle of 50-60° was classified as restenosis.164
3.2 Purpose, study population, design and outcome
3.2.1 Study I
Tested the hypothesis of whether a high volume centre could achieve better results for CAS as 
compared to national results.
In this retrospective single-centre review of all consecutive patients treated with CAS at Söder-
sjukhuset between November 25th 2004 and April 27th 2011 were compared to national data 
from Sweden. Södersjukhuset is, by Swedish numbers, a high volume centre; at that time 45% 
of all Swedish CAS was performed at Södersjukhuset. These data were compared to results 
from CEA performed at Södersjukhuset during the same time period, and also compared to pa-
tients treated with CAS and CEA elsewhere in Sweden. Comparison data were extracted from 
Swedvasc. Only procedures for internal carotid stenosis were included. Indications other then 
stenosis were excluded (trauma, dissections, aneurysms), as were percutaneous transluminal 
angioplasty without stenting. CAS performed on synchronous arch and or intracerebral steno-
sis were excluded.
Primary endpoint was 30-day stroke or death and 30-days stroke/death/AMI rate. The second-
ary endpoint was restenosis after CAS at 1 year.
3.2.2 Study II
Explored whether or not there was a correlation between time from alarm symptoms to CAS 
and perioperative results. In this retrospective nationwide cohort study, all patients registered 
in Swedvasc treated with CAS between January 1st 2005, and March 20th 2014 were included. 
Only procedures for ICA stenosis treated with bare metal stents were included. Patients op-
erated on bilaterally were identified, and if procedures were more than 30 days apart, both 
operations were included in the analysis. In total 323 procedures were included. All patients 
were categorized into different groups depending on the interval between qualifying event 
and intervention: 0-2 days, 3-7 days, 8-14 days, and 15-180 days. To increase power and for 
comparison with other studies, we did two other time categorizations: 0-7 days, 8-14 day, 15-
28 days, and 29-180 days; and 0-7 days, and 29-180 days respectively. Primary outcome was 
30-day stroke or death rate. Secondary outcome was the composite endpoint of AMI, stroke, 
or death at 30 days. 
Participants and Methods
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3.2.3 Study III
Examined the long-term results after CAS. For comparative purposes we used a matched co-
hort treated with CEA. In this retrospective matched cohort study, we included all patients who 
had CAS performed for symptomatic or asymptomatic carotid stenosis from January 1st 2005, 
to December 31st 2012 and were registered in Swedvasc. Only primary CAS were included 
and we used a 7-year retrospective period to identify and exclude earlier operated patients. 
Excluded were also patients treated with covered stents, PTA solely, or combined procedures. 
In total 409 patients treated with CAS were included. For comparison with the study group, we 
used patients operated with CEA (n = 748), matched with respect to age, sex, procedure year, 
and indication (minor stroke, transient ischemic attack, amaurosis fugax, or asymptomatic). 
Since every patient in Sweden has a unique personal identification number, we could cross 
match the whole cohort with the in patient registry. We used International Classification of Dis-
eases- codes I60-69 to identify all strokes during follow up, G45 and G46 for identifying tran-
sient ischemic attacks that had been misclassified, and eventually I48 to identify patients with 
atrial fibrillation. Charts and radiological reports from all in-hospital episodes were retrieved 
and thoroughly read by two investigators to assess the severity (measured by modified Rankin 
Scale) and brain territory of the stroke. The investigators were blinded to treatment type. Pri-
mary outcome was ipsilateral stroke or death from 31 days after index date to the end of follow 
up. Secondary endpoints were all causes of mortality, ipsilateral stroke, death, and any stroke 
or death more than 30 days postoperatively. Since many patients died during follow-up, we did 
a competing risk analysis, with death as competing risk to ipsilateral stroke after day 31.
3.2.4 Study IV
We compared Near-infrared Spectroscopy and stump pressure as predictor of cerebral ischemia 
in patients undergoing CEA under LA. In this prospective multicentre study from January 2013 
- October 2016, 185 patients from two vascular units (Södersjukhuset and Gävle Hospital) 
were included. 
The patients were evaluated neurologically throughout the operation by the anaesthesiologist 
and a nurse in collaboration with the vascular surgeon. An intraluminal shunt (Javid or Pruitt- 
Inahara) was used selectively only if the patient developed new neurological symptoms, or 
neurologic deterioration as compared to the preoperative state. All endarterectomies were per-
formed or supervised by an experienced vascular surgeon. 
The rSO2 measurement was performed using the NIRS Foresight® oximeter (CAS Medical 
Systems Inc., Branford, Connecticut). See figure 6.
A 23-Gauge needle was inserted in the common carotid artery and used for stump pressure 
measurement (mean arterial pressure) after clamping the common carotid artery and external 
carotid artery. A test clamping for five minutes was performed, and the stump pressure was 
measured. The change in rSO2 was measured continuously during the operation and six hours 
thereafter.
In order to evaluate the ability to predict cerebral ischemic symptoms we used receiver operat-
ing characteristic curve (ROC curve) and compared area under curve for the change in rSO2 
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(ΔrSO2) and stump pressure. An area under the curve (AUC) of 0.5 suggest no discrimination, 
a value of 1 suggest perfect discrimination. The ROC curve shows the possible sensitivity and 
specificity for different cut-off points. A cut-off point was chosen for each modality and the 
sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) 
were then calculated from this optimal cut-off point with corresponding 95 % confidence in-
tervals. Since missed cerebral ischemia could have fatal consequences, we prioritized high 
sensitivity for the cut-off point.
Figure 6.  Measurement with Foresight® oximeter. Two sensors are applied on the patient’s 
forehead, and the rSO2 are registered continuously.
 3.3 Statistical methods 
Statistical analysis was mainly performed using the IBM SPSS version 18.0-22.0 (SPSS Inc., 
Chicago, IL, USA). For competing risk analysis in study III, the software R 3.2.2 was used for 
competing risk analysis and bootstrap CI calculations.
3.3.1 Study I and II
Continuous data with normal distribution were presented with mean and standard deviation 
and non-normally distributed data with median and interquartile range. For categorical data a 
two-sided Fisher´s or Chi square test was used. Student’s t-test was used for continuous data. 
Mann-Whitney U test was used for non-parametric data.  The 95% confidence intervals were 
calculated with the modified Wald method. Statistical significance was set at p-value < 0.05. 
Participants and Methods
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3.3.2 Study III
In addition to the statistical analysis used in study I and II, we used the Wald-Wolfowitz test to 
compare distributions of modified Rankin Scale scores. We calculated cumulative incidences 
of outcomes from Kaplan-Meier estimates and compared CAS and CEA with the Mantel-
Haenszel log-rank test. Standard Cox proportional hazards model was used for outcomes, and 
models were adjusted for pre-specified covariates known to affect the outcome after CEA and 
CAS: diabetes mellitus, hypertension, cardiac disease, atrial fibrillation, current smoking, pul-
monary disease, and renal insufficiency. Patients who survived without an event were censored. 
3.3.3 Study IV
In addition to the statistical analysis used in study I and II we used receiver operating Char-
acteristic curve (ROC curve) and compared the area under the curve for changes in rSO2 and 
stump pressures. A cut-off value was chosen to prioritize high sensitivity for each modality, and 
for stump pressure 50 mmHg. Sensitivity, specificity, positive predictive value and negative 
predictive value with corresponding 95 % confidence intervals were then calculated. We used 
the Hanley and McNeil´s method to compare ROC curves for NIRS and SP.165
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4 results
4.1 Study I
During the study period, 208 CAS and 552 CEA procedures were performed in Södersjukhu-
set. During the same period, 258 CAS procedures, and 5922 CEAs were performed elsewhere 
in Sweden.
 CAS at Södersjukhuset
In Södersjukhuset, 38% of all carotid procedures were CAS. Comparing the CAS groups, the 
patients in Södersjukhuset were slightly older and had less heart disease (see table 6).
The most common indications for using CAS were severe comorbidity (27%) or randomiza-
tion within ICSS or ACST-2 (25 %). All indications for using CAS in Södersjukhuset are pre-
sented in table 7. 
A protection device was used in all CAS patients in Södersjukhuset. In 57% of the cases, flow 
reversal (Neuro protection system (NPS); W. L. Gore and Associates, Flagstaff, Ariz, US) was 
used. The rest were treated with a standard filter. Any stroke or death occurred in 3/118 patients 
(2.5%) when reversed flow was used and in 3/90 (3.3%) when filter was used, (p = 1.0). When 
comparing symptomatic vs. asymptomatic carotid stenosis, the stroke or death, the frequency 
was 2.7% (3/111) and 3.1% (3/97) respectively (p = 1.0).
Ninety percent of the patients had a one year duplex follow up. One patient had an asymptom-
atic occlusion, 16 patients (10%) had a restenosis at one year, six patients were revascularized, 
two of whom were symptomatic.
CAS elsewhere in Sweden (Södersjukhuset excluded) and comparison with CAS in 
Södersjukhuset
CAS was performed at nine other centres. On average 29 CAS (range 1-119) were performed 
per center (Södersjukhuset excluded). Comparing Södersjukhuset with national Swedvasc data 
(Södersjukhuset excluded) as shown in table 8, 2.9 % of patients treated at Södersjukhuset had 
a stroke or died, compared to 7.4 % (p= 0.04). Among asymptomatic patients registered in 
Swedvasc, 10.9 % (11/101) had a stroke within 30 days, as compared to 2.7 % in Södersjukhu-
set.
CEA in Södersjukhuset and in Sweden (Södersjukhuset included)
In patients operated with CEA in Södersjukhuset, 4.0% had a stroke or died within 30 days. 
Stroke and death rates among asymptomatic patients was 3.7%, and for symptomatic patients 
it was 5.0 %. Corresponding values for CEA registered in Swedvasc including Södersjukhuset 
was 4.4%, 4.4%, and 4.0% respectively. There were no significant differences between the lo-
cal and national results with respect to perioperative outcome after CEA (see table 8).
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Table 6. Baseline characteristics for CAS patients treated at Södersjukhuset and national 
Swedvasc data 
Södersjukhuset (n=208) Swedvasc (n=258)* p-value †
Male Sex 68% (141) 74% (192) NS
Age mean (SD) 71 (8.5)  69 (8.3) 0.01
Symptomatic 
    TIA 
    Ischemic stroke  
    Amaurosis fugax 
Asymptomatic
53% (111) 
47% (52) 
38% (42) 
15% (17) 
47% (97)
58% (149) 
35% (52) 
43% (64) 
22% (33) 
42% (109)
NS
Days from index symptom  
until CAS‡, 8 (IQR 5-28) 13 (IQR 6-25) NS
 
Smoking 37% (66) 43% (81) NS
Diabetic 29%  (61) 29% (61) NS
Pulmonary disease 11% (22) 18% (28) NS
Renal dysfunction 
(creatinine>150μmol/L)
4% (8) 5% (11) NS
Heart disease 46% (94) 61% (108) <0.01
Treated hypertension 81% (169) 81% (173) NS
High risk CAS # 
Average risk CAS
35%  (72) 
65% (132)
41% (56) 
59% (80) NS
 
NS indicates Non significant; CAS indicates Carotid artery stenting, CEA indicates Carotid endarterectomy; TIA 
indicates Transient Ischemic Attack. 
* Södersjukhuset excluded from national data. †  Fisher’s test for dichotomous data and t-test for continuous data, 
Mann Whitney test for waiting time variable. ‡Data available only in swedvasc 2.0. # High risk defined as two or 
more risk factors out of: age>70 years, heart disease, pulmonary disease, renal dysfunction. 
Table 7. Indications for CAS at Södersjukhuset
% (n)
Randomized within ICSS/ACST2 25 (51)
Restenosis after previous CEA/CAS 11 (22)
Severe comorbidity 27 (56)
Post-radiation therapy 6  (12)
Surgically inaccessible stenosis 7  (15)
Contralateral laryngeal nerve injury 0.5   (1)
Patients preference 8  (17)
Previous neck surgery 1  (2)
No specified reason 15  (32)
Total 100.0  (208)
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Table 8. 30-day outcomes in patients treated with CAS at Södersjukhuset compared to 
Swedish national CAS data, and CEA at Södersjukhuset compared to Swedvasc.
carotid artery stenting, cas carotid endarterectomy, cea
Södersjukhuset 
CAS 
%, (n)
Swedvasc  
CAS† 
%, (n)
p-value * Södersjuk- 
huset  
CEA 
%, (n)
Swedvasc 
CEA 
%, (n)
p-value *
Patients, n 208 258 552 6474
Any stroke 1.9 (4) 5.4 (13/242) NS 3.8 (21/549) 4.0 (250/6322) NS
Death 1.0 (2) 2.3 (6) NS 0.5 (3/552) 0.8 (53/6472) NS
AMI 1.4 (3) 2.9 (7/242) NS 2.7 (15/548) 1.8 (113/6314) NS
Stroke or death 
- Among symptomatic  
- Among asymptomatic  
- Among high risk  
- Among average risk
2.9 (6) 
2.7 (3/111) 
3.1 (3/97) 
5.6 (4/72) 
1.5 (2/132)
7.4 (18/243) 
4.9 (7/142) 
10.9 (11/101) 
16.7 (9/54) 
3.9 (3/76)
0.04 
NS 
0.0495 
NS 
NS
4.0 (22/549) 
3.7 (16/428) 
5.0 (6/121)
4.4 (277/6322) 
4.4 (220/5007) 
4.0 (53/1315)
NS 
 
NS
Stroke or death or AMI 3.4 (7) 9.5 (23/243) 0.01 6.2 (34/548) 5.8 (368/6321) NS
 
NS Non significant; CAS Carotid artery stenting, CEA Carotid endarterectomy; TIA Transient Ischemic Attack. 
* Fisher´s exact test. † SÖS excluded from national data
4.2 Study II
During the study period, 323 patients with an average age of 71 years underwent CAS due to 
symptomatic carotid stenosis. The qualifying neurologic event was TIA (42.7%), minor stroke 
(36.5%), amaurosis fugax (18.9%), major stroke (1.5%) and crescendo TIA (0.3%). Looking 
at the median, the intervention was performed 13 days after qualifying event (IQR 7-29). An 
embolic protection device was used in 90.6% of the patients, most often filter (58%) followed 
by reversed flow (Neuro Protection System, WL Gore®). Thirteen patients were treated within 
2 days from qualifying event, 85 between 3-7 days, 80 patients between 8-14 days, and 145 
patients between 15-180 days. There were no major differences between the different groups 
with respect to comorbidities, protection device used, degree of stenosis, reason for CAS, or 
postoperative medical treatment (see table 9).
The combined stroke or death rate were similar in the different time periods; 0% in the group 
treated 0-2 days, versus 4.7% at 3-7 days, 6.3% at 8-14 days, and 4.1% for the patients treated 
at 15-180 days (p = 0.76). Also in our secondary analysis, with four different time periods the 
combined stroke and death rate were similar for all subgroups; 4.1% for the group treated 0-7 
days, versus 6.3 % treated at 8-14 days, 4.8 % at 15-28 days, and 3.6 % at 29-180 days (Table 
10 and 11). 
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In the first half of the study period (Jan 2005 - Aug 2009), 4.9% of the symptomatic carotid 
stenoses in Sweden were treated by CAS (n = 187) which decreased to 3.4% in the second part. 
The time from qualifying event to intervention decreased from 15 to 10 days during the study 
period. The 30-day stroke and death rate increased from 4.9% to 5.9%. In the first half of the 
study period, nine centres performed CAS, seven of them continued in the second period. None 
of these differences were statistically significant.
The 30-day stroke and death rate for the whole cohort was 5.9% in patients without EPD, 4.2% 
with the use of filter and 4.0% in patients with reversed flow (p=0.895). Corresponding rates 
for patients treated within 7 days (n=98) was 16.7%, 2.1% and 2.6% respectively (p=0.062).
Table 10. Procedural adverse events
Time to CAS (days)
0-2, N = 13 
n (%)
3-7, N = 85 
n (%)
8-14, N = 80 
n (%)
15-180, N = 145 
n (%)
p-value*
stroke 0 (0.0) 3 (3.5) 5 (6.3) 5 (3.5) 0.626
aMi 0 (0.0) 3 (3.5) 2 (2.5) 2 (1.4) 0.602
deaths 0 (0.0) 0 (0.0) 3 (3.8) 1 (0.7) 0.126
stroke/death 
(95%ci) 
0 (0.0) 
(0-26.6)
4 (4.7) 
(1.5-11.9)
5 (6.3) 
(2.4-14.1)
6 (4.1) 
(1.7-8.9) 0.757
stroke/death/aMi 
(95%ci) 
0 (0.0) 
(0-26.6)
7 (8.2) 
(3.8-16.3)
6 (7.5) 
(3.2-15.7)
8 (5.5) 
(2.7-10.7) 0.640
 
AMI indicates Acute Myocardial Infarction; CAS indicates Carotid Artery Stenting; CI indicates Confidence 
intervals. 
*p-values were calculated by Chi square
Table 11. Procedural adverse events (secondary time classification)
Time to CAS (days)
0-7, N=98 
n (%)
8-14, N=80 
n (%)
15-28, N=62 
n (%)
29-180, N=83 
n (%)
p-value*
Stroke 3 (3.1) 5 (6.3) 2 (3.2) 3 (3.6) 0.706
AMI 3 (3.1) 2 (2.5) 1 (1.6) 1 (1.2) 0.688
Deaths 0 (0.0) 3 (3.8) 1 (1.6) 0 (0.0) 0.091
Stroke/death 
(95%CI) 
4 (4.1) 
(1.3-9.0)
5 (6.3) 
(2.4-14.2)
3 (4.8) 
(1.1-13.8)
3 
3.6(0.1-10.5)
0.864
Stroke/death/AMI 
(95%CI) 
7 (7.1) 
(3.3-14.3)
6 
7.5(3.2-15.7)
4 
6.6.5(2.1-15.9)
4 
4.8(1.5-12.1)
0.900
AMI indicates Acute Myocardial Infarction; CAS indicates Carotid Artery Stenting; CI indicates Confidence 
intervals. 
*p-values were calculated by Chi square
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4.3 Study III
The final study population in study III consisted of 1157 patients: 409 CAS and 748 CEA (con-
trol group matched with respect to indication, sex, age and procedure year), see flow chart be-
low (figure 8). The majority (69%) was treated due to symptomatic stenosis. During follow up, 
the cohort had 394 hospitalization episodes with stroke or TIA diagnosis registered in the in pa-
tient registry. After retrieving 393 out of 394 charts, 133 postprocedural strokes were identified, 
and 12 patients had more than one stroke. Within 30 days, 3.4% in the CAS group and 3.2% 
in the CEA group had a stroke or died, p = 0.86. After the perioperative phase, 96/409 patients 
treated with CAS and 121/748 with CEA had a new ipsilateral stroke or died, corresponding 
to a rate of 7.25 (95% CI 5.91 – 8.82) per 100 person-years in CAS-patients compared to 4.53 
(95% CI 3.78 – 5.40) in CEA-patients. In the Cox regression analyses, patients treated with 
CAS had an overall higher risk, HR 1.63 (95% CI 1.24-2.13), for ipsilateral stroke or death 
after day 30 compared to those treated with CEA in crude analysis. The matching of the control 
group was close, and the groups were fairly similar with respect to comorbidities (see Table 
12). We adjusted the Cox regression analysis for known confounding factors. The adjusted risk 
was essentially unchanged, HR 1.59 (95% CI 1.16-2.19), see Table 13. All outcomes regarding 
stroke after 30 days showed higher risk for CAS, whereas all cause mortality was similar for 
CAS and CEA. We also performed a competing risk analysis (with death as competing risk 
to ipsilateral stroke), which showed an even more pronounced increased risk for stroke. The 
severity of stroke, measured by modified Rankin Scale was similar in both groups. The Kaplan 
Meier curves for major outcomes are presented in Figure 7a-7d.
                                         Type of intervention
    CAS (%) (95%CI) CEA (%) (95%CI) P-value
Patients, n 409 748
Male sex, n (%) 300 73.3 (68.9 – 77.7) 552 73.8 (70.6 – 76.9) 0.889
Age, years (SD) 70.0 8.7 (69.4 – 70.6) 70.3 7.8 (69.7 – 70.9) 0.628*
Current smokers 96 23.5 (19.5 – 27.8) 190 25.4 (22.4 – 28.7) 0.477
Co morbidities, n (%)
Cardiac disease 164 40.1 (35.4 – 44.9) 257 34.4 (31.0 – 37.8) 0.055
Pulmonary disease 47 11.5 (8.7 – 14.9) 59 7.9 (6.1 – 10.0) 0.055
Diabetes mellitus 105 25.7 (21.6 – 30.1) 149 19.9 (17.2 – 22.9) 0.026
Hypertension 298 72.9 (68.4 – 77.0) 554 74.1 (70.8 – 77.1) 0.676
Renal insufficiency 13 3.2 (1.8 –5.2) 30 4.0 (2.8 – 5.6) 0.520
Indication, n (%) 0.953†
Asymptomatic 133 32.5 (28.1 – 30.2) 231 30.9 (27.7 – 34.3)
Amaurosis fugax 44 10.8 (8.0 – 14.1) 82 11.0 (8.9 – 13.4)
TIA 122 29.8 (25.5 – 34.4) 227 30.3 (27.1 – 33.7)
Minor stroke 110 26.9 (22.8 – 31.4) 208 27.8 (24.7 – 31.1)
CAS = carotid artery stenting; CEA = carotid endarterectomy; TIA = Transient Ischemic Attack. CI = confidence 
interval. P-values were calculated by Fisher´s exact test, * t-test, and † chi square. Confidence intervals were 
computed with Mid-P Exact test for proportions and t-test for age.
Table 12. Baseline characteristics
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Results
Figure 7. Kaplan-Meier curves for major outcomes. A. Ipsilateral stroke or death for 
> 30 days after treatment. B Any stroke or death for > 30 days after treatment. C Ip-
silateral stroke for > 30 days after treatment. D Death. The numbers below the pan-
els are the numbers of patients in each group that are event free and still at risk.
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 Carotid	  procedure	  code	  in	  Swedvasc	  
n=16961	  
  
Primary	  Carotid	  procedure	  code	  
n	  =	  15	  303	  
  
Previously	  operated	  
n	  =	  1420	  
  
Missing	  vital	  data	  n	  =	  18	  
Dissection	  n	  =	  12	  
Aneurysm	  n	  =	  36	  
Other	  non	  carotid	  n	  =	  167	  
Bilateral	  n	  =	  5	  
	  
Patients	  operated	  
before	  2005/01/01	  
n	  =	  7136	  
after	  2012/12/31	  
n	  =	  	  341	  
  
Final	  study	  population	  	  
n	  =	  7	  826	  
CEA	  n	  =	  7	  417	  
CAS	  n	  =	  409	  
  
Primary	  CAS	  	  
n	  =	  409	  
 
Matched	  
controls	  (CEA)	  
n	  =	  748	  
 
 
Figure 8. Flow chart
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Figure 9. Modified Rankin Scale when admission to hospital during follow up
4.4 Study IV
We prospectively included 185 patients. During carotid clamping, twenty patients developed 
neurologic symptoms (10.8%). Baseline characteristics were similar for those who developed 
neurological symptoms and those who did not (Table 14). Mean stump pressure (MAP) was 
lower in the group that developed neurologic symptoms than in those who did not, 34 ± 19 
mmHg versus 55 ± 17 mmHg (p < 0.01). A box plot of all SP is presented in figure 10. The 
relative change in rSO2 on the operated side (ΔrSO2 ipsi) decreased more after clamping in 
the group that developed neurologic symptoms than in those who did not, -15 ± 7% versus -4 
± 6% (p<0.01). The change in rSO2 during the endarterectomy is presented in Figure 11 and 
the operative data in Table 15. After shunt insertion, the rSO2 on the ipsilateral side returned 
to equivalent level as before clamping, ΔrSO2 increased with 12 ± 7% after 1 minute; and 14 
± 8% after 5 minutes, as compared to measurements during clamping. The AUC for ΔrSO2 
and SP was 0.92 (95 % CI 0.87-0.95) and 0.81 (95 % CI 0.74-0.86) respectively. Pairwise 
comparison of ROC curves using Hanley and McNeil´s method was difference between areas 
0.11(95% CI -0.02-0.24). See figure 12 for the ROC curve.
Using SP ≤ 50 mmHg as the cut-off value, we found an 85% (95% CI 64-95) sensitivity and 
54% (95% CI 46-61) specificity for SP to detect cerebral ischemia. The PPV was 19% (95% CI 
12-28) and NPV 96% (95% CI 90-99). We prioritized high sensitivity when choosing a cut-off 
value for ΔrSO2. A value of 9% decrease was identified to be optimal for detecting cerebral 
ischemia. With this cut-off value, the sensitivity was 95 % (95% CI 76-99) and specificity 81 
% (95% CI 75-86). The PPV was 38% (95% CI 26-52) and NPV 99% (95% CI 96-100%). See 
table 16.
Neurologic deterioration during carotid clamping was detected in one patient with a ΔrSO2 ≥ 
9%, and three patients with a SP > 50 mmHg. The ROC curve is presented in figure 12.
Three patients (15%) in the group that developed neurologic symptoms during clamping had a 
stroke within 30 days, compared to 1 patient (0.6%) among those who did not develop neuro-
logical symptoms during clamping (p = 0.004). See table 17 for 30-day outcome.
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Variable Neurologic symptoms 
during CEA n, (%) 
N=20
No-neurologic symptoms 
during CEA n, (%),  
N=165
p-Value
Sex, male 11 (55.0) 115 (68.5) 0.313
Side, Right 11 (55.0) 79 (47.9) 0.638
Age (years; Mean; sd) 74; 7 71; 8 0.631*
Diabetes Mellitus 3 (15.0) 27 (16.4) 1.000
Hypertension 18 (90.0) 127 (77.0) 0.254
Heart disease 7 (35.0) 50 (30.3) 0.798
Pulmonary disease 3 (15.0) 18 (10.9) 0.706
Renal insufficiency 3 (15.0) 13 (7.9) 0.389
Current smoker 0 (0.0) 27 (16.4) 0.049
Symptomatic 19 (95.0) 138 (83.6) 0.206
Indexsymptom 0.145
Amaurosis fugax 1 (5.0) 40 (24.2)
TIA 11 (55.0) 56 (33.9)
Crescendo TIA 0 (0.0) 2 (1.2)
Minor stroke 7 (35.0) 40 (24.2)
Asymptomatic 1 (5.0) 29 (17.6)
Time from symptom to opera-
tion (days); median; IQR
5.0; 8.0 7.0; 8.0 0.306†
Degree of ipsilateral stenosis 0.872‡
20-49% 1 (5.0) 12 (7.3)
50-69% 4 (20.0) 38 (23.0)
70-99% 15 (75.0) 115 (69.7)
Degree of contralateral stenosis 0.357‡
<20% 11 (55.0) 91 (55.2)
20-49% 2 (10.0) 34 (20.6)
50-69% 5 (25.0) 18 (10.9)
70-99% 2 (10.0) 18 (10.9)
Occlusion 0 (0.0) 4 (2.4)
CEA indicates Carotid endarterectomy; IQR, Interquartile Range; TIA, transient ischemic attack; sd, standard deviation 
Fisher exact test if other method is not presented *T test, †Mann Whitney U test, ‡Chi-square test
Table 14. Baseline characteristics for the 185 patients
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Table 15. Operative data; mean value and standard deviations (sd).
No- neurologic 
symptoms during 
clamping, N = 165
Pre clamp-
Mean (sd)
Clamp  
1 min 
Mean (sd)
Clamp  
5 min 
Mean (sd)
Post Clamp  
1 min 
Mean (sd)
Post Clamp  
5 min 
Mean (sd)
MAP (mmHg) 95 (15) 100 (15) 101 (15) 95 (14) 92 (14)
rSO2ipsi (%) 72 (5) 69 (6) 69 (6) 72 (5) 73 (10)
ΔrSO2 ipsi* (%) Ref -4 (6) -4 (5) 1 (5) 1 (5)
rSO2kontra (%) 73 (5) 72 (5) 72 (5) 73 (5) 73 (5)
SP (mmHg) range 55 (17) 3-110
Neurologic symp-
toms during clamp-
ing, N = 20
Pre clamp-
Mean (sd)
Clamp  
1 min 
Mean (sd)
Shunt in-
serted  
1 min (n=16)
Mean (sd)‡
Shunt in-
serted  
5 min (n=16)
Mean (sd)‡
Post Clamp 
1 min 
Mean (sd)
Post Clamp 
5 min 
Mean (sd)
MAP (mmHg) 88 (11) 92 (20) 96 (15) 96 (18)
rSO2ipsi 71 (5) 61 (6) 67 (6) 68 (5) 72 (5) 73 (5)
ΔrSO2 ipsi (%) Ref. -15 (6)* 12 (7)† 14 (8)† 1 (6)* 2 (6)*
rSO2kontra (%) 73 (5) 71 (7) 71 (6) 72 (6) 73 (8) 71 (6)
SP (mmHg) range 34 (19) 0-73
MAP indicates Mean arterial pressure (systemic blood pressure); SP, Stump pressure; sd, standard deviation 
*Relative change in rSO2 compared to pre clamp †Relative change in rSO2 compared to during clamping 1 min ‡Twenty 
patients developed neurological symptoms during clamping, 16 of whom received a shunt.
Table 16. Results of NIRS and stump pressure to detect cerebral ischemia compared  
to awake testing.
Neurologic 
symptoms 
during CEA 
(n=20)
No-neurologic 
symptoms during 
CEA 
(n=165)
Sens (%) 
(95% CI)
Spec (%) 
(95% CI)
PPV (%) 
(95% CI)
NPV(%) 
(95% CI)
ΔrSO2 < 9.0 %* 1 134 95  
(76-99)
81 
(75-86)
38 
(26-52)
99 
(96-100)ΔrSO2 ≥ 9.0 %* 19 31
SP > 50 mmHg 3 84 85 
(64-95)
54 
(46-61)
19 
(12-28)
96 
(90-99)SP ≤50 mmHg 17 73
CEA indicates Carotid endarterectomy; SP, stump pressure; NPV, Negative predicted value; PPV, Positive predicted value. 
*Relative change in rSO2 after carotid clamping compared to before carotid clamping
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Table 17. 30-day results
Figure 10. Box plot of stump pressure 
Outcome within 30 
days
All patients 
N=185 
n (%)
Neurologic symp-
toms during clamp-
ing, N=20 
n (%)
No-neurologic 
symptoms during 
clamping,  
N=165 
n (%)
p-value*
AMI 3 (1.6) 0 (0.0) 3 (1.8) 1.000
TIA 5 (2.7) 0 (0.0) 5 (3.0) 1.000
Stroke 4 (2.2) 3 (15.0) 1 (0.6) 0.004
Death 1 (0.5) 0 (0.0) 1 (0.6) 1.000
Stroke/death 5 (2.7) 3 (15.0) 2 (1.2) 0.009
AMI indicates acute myocardial infarction; TIA, transient ischemic attack 
*Fisher exact test. P-value for comparing patients with and without neurologic symptoms.
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Figure 12. ROC curve to evaluate the ability of NIRS and stump pressure to predict cerebral 
ischemia during carotid clamping. Cut-off value for ΔrSO2 ≥ 9.0 %, cut-off value for stump 
pressure ≤ 50mmHg
Results
Figure 11. Change of rSO2 during different stages of endarterectomy
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5 discussion
5.1 General discussion and main findings
5.1.1 The relevance of patient volume
Our results in study I show that in a centre with experienced staff and high volumes of CAS, 
you can produce comparatively good results. But the nationwide stroke or death rates at 30 
days are higher among patients treated with CAS than CEA. This is not unique for Sweden, as 
similar findings are reported from several registry studies where it has been shown that the 30 
day results for CAS is not as good as in the randomised controlled trials.78  A significant obser-
vation in our study is the 10.9% stroke or death rate at 30 days for patients treated with CAS 
for asymptomatic stenosis outside Södersjukhuset. 
Comparing the stroke and death rate among symptomatic patients treated with CAS in Söder-
sjukhuset and Sweden (2.7% and 4.9% respectively) with CAS patients in earlier randomised 
controlled studies SAPPHIRE (29% symptomatic patients) was 5.5%79, EVA-3S 9.6%80, 
SPACE 7.7%81, ICSS 8.5%82 and among symptomatic patients in CREST 6.0%83 the Swedish 
national results are not so extreme.
Very few centres in Sweden performed CAS before 2004, and Södersjukhuset started with 
CAS in November 2004, thus our data includes a learning curve. Nine centres performed CAS 
in 2004-2008, seven centres after 2008 and only six after 2010. In the early phase the total 
stroke and death rate after all CAS was 6.4 %. There has probably been an adaption to the early 
poor results, and some of the smaller units have stopped performing CAS, and the results for 
CAS improved during the study period. A possible explanation of the low frequency of compli-
cations in our single centre is due to high volume and experience of the team (only two opera-
tors performed all interventions). Also, the 10.9% stroke and death rate among asymptomatic 
patients in Sweden outside Södersjukhuset were on a very limited number of patients (11 out 
of 101 patients) in 5 different centres.
Limited experience among interventionists participating in some of the randomised controlled 
trials has been proposed as an explanation for the high rate of complications in e.g. EVA-3S 
and ICSS as compared to CREST, where 30 CAS was required for credentialing. It has been 
shown in several studies that the stroke and death rate among experienced operators was lower 
than for inexperienced operators, and an annual volume of at least 6 CAS/operator has been 
proposed.166-169 A systematic review confirms that the results of CAS have improved over time, 
and a learning curve is likely to exist, and in active CAS units it may take around two years 
before stroke and death rate declines to around 5%.170 In contrast to this, analysis within EVA-
3S, patients treated by investigators that had done more than 50 carotid stent procedures had 
higher rate of stroke and death than those who had experience of fewer than 50 carotid stent-
ings. Likewise, in the ICSS, the more experienced centres had a higher stroke or death rate.171 
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However, this could be ‘chance’, or possibly due to the treatment of more diseased patients. It 
is unlikely, that centres performing very few stenting procedures per year could achieve similar 
results to high volume centres. With the low number of CAS being performed every year in 
Sweden, they should be centralized into only a very few centres.
In previous meta-analyses, the superiority of CEA disappeared for patients younger than 70 
years172-174 We also found CAS to be better in younger patients in Södersjukhuset, but the dif-
ference was small (2.4% vs 4.0% for stroke/AMI/death, p = 0.7) .
The alarming 10.9% stroke or death rate among CAS for asymptomatic stenosis raises ques-
tions, as well as the stroke or death rate of 4.0% among 1315 asymptomatic CEA patients, thus 
questioning the benefits of this operation.
 This study has some limitations. The sample size on CAS procedures is small and does not 
allow us to compare outcome adjusted for comorbidities with national data. The data from 
Swedvasc has high validity, but is not as complete as the single centre series, and have missing 
values on baseline characteristics and 30-day outcome. But the missing outcome data in Swed-
vasc would probably increase the frequency of complications since missing data in general 
tends to have less favourable results. 
The strength of our single centre cohort is that it is a consecutive series. We have no missing 
cases for the 30-day follow-up, and the combination with the population registry makes the 
validity for the stroke and death variable very reliable. 
5.1.2 Timing of carotid intervention
-The time relation between neurologic symptoms and intervention.
In our nationwide study, we did not find any differences between patients who underwent CAS 
within two days or within one week from alarm symptom. Although relatively few patients 
were treated within the first two days after alarm symptom, no major peri-procedural complica-
tion or death occurred among those patients. 
The available data regarding risk of CAS stratified for time between neurologic symptoms and 
intervention is very limited.  The CAPTURE registry reported an increased rate of stroke and 
death when CAS was performed within two weeks after onset of neurologic symptoms com-
pared to other symptomatic patients (OR 2.15, 95%CI 1.14-4.08).166 Small single-centre series 
have reported disparate results: Setacci et al., showed a stroke and death rate of 3.8% if pa-
tients were treated within 48 hours,123 Wach et al., 7.1% for patients treated within 48 hours119, 
whereas Topakian et al., reported a 26% stroke and death rate for patients treated within 14 
days, compared to 1.9% if treated after 14 days.121 The largest analysis of stenting and time re-
lation from qualifying event to treatment is pooled data from SPACE, ICSS, and EVA 3-S with 
data on a total of 1434 CAS procedures, where only 138 of those were within 1 week. They 
found that the risk of CAS, compared to CEA, was especially high within the first week after 
symptoms, RR 3.44 (95% CI 1.0-11.8).120
For CEA the results diverge as well: a meta-analysis and a large cohort study could not identify 
a higher perioperative stroke- and death rate for CEA in the subacute phase.116, 175 Some single-
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centre series have demonstrated good results for CEA in the acute phase 177-180 whereas other 
have shown inferior results in the acute phase.112,176 One Swedvasc study showed very high 
incidence of perioperative complications for patients operated with a CEA within 48 hours.113 
In contrast, two recent studies could not support that time after index event influenced the peri-
operative stroke or death rate.114, 115
However, since the early risk of recurrent stroke for patients with symptomatic stenosis with 
recent neurologic event with medical therapy solely is so high, 93, 94, 97, 103-105, 181-183 there might be 
justification in urgent treatment, even if the complication rate would be increased. 184, 185
Possibly the diverging results between studies regarding time relation between neurologic 
symptoms and carotid intervention is due to different study populations, inconsequent termi-
nology and low power. 
The strength of our study is that it is a large population-based study investigating the risks of 
urgent CAS. It has national coverage and reflects the clinical reality in a country. Data quality 
on outcomes is good with few missing values. Small numbers of patients that had undergone 
a procedure within 2 days from onset of symptoms limits our report with respect to this urgent 
group. Still, it illustrates that the complication rate after CAS, performed within 1 week from 
alarm symptom, is within acceptable limits.
5.1.3 Embolic protection device
The flow reversal system has some potential advantages compared to filters and the early re-
ports had low stroke rate.186, 187 Proximal balloon occlusion systems produce less micro emboli 
registered with TCD than filters.188 But on the other hand, proximal occlusion is reported to 
produce more emboli than filters on post op MR in a small trial.189 
In study I, we could not detect any difference in outcome stroke or death at 30 days if reversed 
flow or filter was used among patients treated in Södersjukhuset (2.5% vs 3.3%, p=1.0). 
In the acute phase after a stroke and TIA, the plaques are in general unstable, and it takes 
around two weeks for the plaque to stabilize. In this acute phase, reversed flow would be even 
more appealing, than passing a fresh thrombus with a stiff guide wire. Patients treated without 
EPD had an increased rate of stroke or death within 30 days compared to filter and reversed 
flow. In the group treated with no EPD and within 7 days from onset of symptoms (n=12), the 
stroke and death rate was 16.7% compared to filter 2.1% and reversed flow 2.6% (p=0.062). 
Due to low numbers, none of these differences were statistically significant.
5.1.4 Long-term results after carotid artery stenting
In our nationwide cohort study, including all primary CAS procedures in Sweden, we observed 
an increased risk for late stroke or death after CAS as compared to CEA. There were no differ-
ences with respect to death between the groups, and the increased risk in the CAS group was 
mainly due to an increased risk of ipsilateral stroke. The matched design, the similar mortality 
rate and the small changes in hazard ratios after adjusting for confounders indicate a low de-
gree of confounding and bias.
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The two year follow up after SPACE, the five-year results of the EVA3-S and the 7.4 year fol-
low up from CREST trial study showed no significant difference between CAS and CEA with 
respect to ipsilateral stroke in the post-procedural period.87, 89, 92 However, in the ICSS long- 
term follow-up, where patients were followed for a median of 4.2 years, there was a higher 
incidence of total stroke after 30 days in the CAS group, HR 1.53 (95% CI  1.02-2.31). In the 
ICSS, the difference was, mainly driven by strokes occurring in the contralateral or vertebro-
basilar territory.190 This could be explained by chance, but as can be seen in the ACST-1, the 
risk of contralateral stroke was reduced after CEA, and probably some hypoperfusion strokes 
could be avoided.
The CAVATAS trial, SPACE and EVA 3-S have all reported an increased rate of restenosis after 
CAS compared to CEA.86-88 In the ICSS long-term follow-up, no difference in the long-term 
rates of severe restenosis or occlusion was found.190 While restenosis in general was a signifi-
cant risk factor for recurrent ipsilateral stroke in the CREST trial, there was no difference in 
rate of restenosis between CAS and CEA (12.2% and 9.7%) after 7.2 years.89, 90 
There is no uniform protocol for follow-up after CEA or CAS in Sweden, and the Swedvasc 
registry does not include information about surveillance details after treatment. Accordingly, 
the natural course of recurrent stenosis after CEA and CAS cannot be studied or adjusted for in 
our study. Nevertheless, restenosis may be one explanation for the inferior results of stenting 
shown here.
The present study has some limitations. The two groups, although matched, cannot compete 
with data from randomized controlled trials. The baseline characteristics were fairly similar in 
the two groups, but both measured and unmeasured differences between the groups may have 
affected the results.
Another limitation is the lack of information on the rationale behind the chosen treatment 
method. Indications, such as hostile neck or anatomically high stenosis, may confound our 
results. On the other hand, it is likely that such confounding factors would affect the short-term 
more than long-term outcomes. 
The strengths of this study are the nationwide, real-world nature of the data combined with 
high reliability of mortality data and low number of missing data on stroke outcomes (1/394). 
In addition, the size of the study makes the risk of a type II statistical error less likely.
Adjusting for possible confounders at baseline, such as diabetes, heart disease, pulmonary dis-
ease and atrial fibrillation did not alter the hazards substantially. The CEA group was matched 
with respect to age, sex, procedure year, and indication (minor stroke, transient ischemic at-
tack, amaurosis fugax, or asymptomatic). The all-cause mortality did not differ between the 
groups, which supports the suggestion that CAS patients were comparable to CEA patients at 
baseline. Moreover, there were no differences in antithrombotic medication or history of atrial 
fibrillation between the CAS and the CEA groups at the time of stroke events > 30 days after 
surgery, thus a difference in strokes caused by cardio-embolism is not likely.
Our results differ from the long-term results in the RCTs and one can only speculate on the 
mechanisms behind this. One concern with the RCTs is that patients and centers are highly 
selected, causing questionable generalizability. Regarding the long-term results from CREST, 
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only 64% of the patients gave consent for the long-term follow up, and 52% were asymptom-
atic.89 A systematic review of registry data found higher stroke/death rates after CAS than after 
CEA in the perioperative period. The adverse events after CEA were similar in the registries to 
the RCTs, whereas CAS had a significantly higher proportion of adverse events, compared to 
the RCTs.78 Although the mechanism is unclear, the “real world” long-term results after CAS 
could be inferior to those in the RCTs. 
5.1.5 Shunting during carotid endarterectomy
In this prospective multicentre trial, decrease in rSO2 was more accurate than stump pres-
sure in predicting cerebral ischemia during clamping of the carotid artery. With a 9% de-
crease in ΔrSO2 as compared to pre-clamping, the sensitivity was 95%, and specificity 81%, 
and a NPV of 99%. Corresponding values for stump pressure with a cut-off value of ≤ 50 
mmHg was 85%, 54%, and 96%. It is possible to increase the sensitivity, but with the disad-
vantage of lower specificity. With a 5% decrease in rSO2, the sensitivity is 100%, specificity 
51%. To achieve 95% sensitivity with SP, the specificity would have been unacceptably low, 
16% (cut-off 73mmHg).
The use of shunting in CEA is debated. Some surgeons prefer routine shunting while others 
advocate selective use. Not more than 10-15% of all patients undergoing endarterectomy 
develop neurological symptoms as a sign of cerebral ischemia when operated on under lo-
cal anaesthesia. Thus, in a shunt-all policy 85-90% of the patients are shunted unnecessar-
ily.129-133, 149, 154, 158-160
Our results show that if 50 mmHg is used as cut-off level for shunt use, nearly half of the 
patients would have been shunted, and still, three patients, with neurologic deterioration 
during clamping would have been missed (false negative). Three missed patients out of 20 
may imply that 15% of the patients that would have needed a shunt would not have gotten 
it! That is similar to the results from Evans et al.,131 who found 3/13 shunt cases had a SP > 
50 mmHg, while Calligaro et al., and Hans et al., reported less false negative results (3/34 
and 3/32 respectively).129, 132  The lower incidence of false negative results presented by Cal-
ligaro et al., and Hans et al., is probably due to the low rate of symptomatic patients in their 
series since symptomatic patients are probably more susceptible to cerebral ischemia during 
clamping.
Only a few small studies have been published comparing NIRS with awake testing. De-
pending on the cut-off value different sensitivities and specificities have previously been 
reported.133, 149, 154, 158-160 In our study, we only had one false negative (0.5%) with NIRS, and 
the sensitivity was 95%.  This is an important benefit of the method compared to SP. Ritter et 
al., had similar sensitivity with a cut-off value of 19 % measured with INVOS 4100®(Troy, 
MI, USA).133 The high sensitivity and negative predictive values are further supported by 
findings of Pennekamp et al., and Mauermann et al., in patients operated under general an-
aesthesia compared to EEG.151, 152 We did not have enough power to prove a statistically sig-
nificant difference for the ROC curves for NIRS and SP (95%CI -0.02-0.24). However, to 
achieve 95% sensitivity for SP, which is a clinically acceptable level, the specificity would 
have been 16% (95% CI 10-47). An additional advantage with the NIRS compared to SP is 
the possibility of continuous monitoring during endarterectomy and of shunt function dur-
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ing clamping. After shunt insertion, the rSO2 increased by 14 ± 8 % five minutes after shunt 
insertion as compared to during clamping. 
The study-population consisted of 84% symptomatic patients, and the median time from 
symptom to operation was six days. Taking this into account, we present good perioperative 
results with an overall 30-day stroke or death rate of 2.7%. Interestingly, in the group that 
developed neurologic symptoms during carotid clamping, three patients (15%) had a stroke, 
as compared to only one patient (0.6%) amongst those who did not develop symptoms 
(p = 0.004). None of the strokes were caused by a known shunt problem. Although these 
results should be interpreted with caution due to the small numbers, patients who develop 
neurological symptoms during carotid clamping might have an increased risk of suffering a 
perioperative stroke despite the use of a shunt. Calligaro et al., also observed an increased 
risk of perioperative stroke in this group: 5.9% versus 0.9%.129  
To our knowledge, this is the largest study of NIRS in patients under LA and also the largest 
cohort comparing SP and NIRS. Compared to earlier studies of SP we present a high propor-
tion of symptomatic patients that were treated shortly after an alarm symptom.
An existing occlusion of the contralateral carotid artery has been reported to be a risk factor for 
low SP and consequently shunt need.132, 191, 192 In the present study, only four patients (2.2%) 
had a contralateral occlusion. None of them developed neurological symptoms, but using 9% 
cut-off value for NIRS, two out of four would have been predicted falsely positive. Using SP ≤ 
50 mmHg as cut-off for shunting, three out of four would have been falsely predicted as posi-
tive. The numbers are too small to draw any conclusions, but in this subgroup with contralateral 
occlusion, it seems to be difficult to predict cerebral ischemia. Some patients with contralateral 
occlusion may have been chosen for operation under general anaesthesia with routine shunt 
use by the treating surgeon. The same could be true for patients with larger structural infarcts 
found on preoperative CT scans.
There are some limitations in our study. One concern is if our findings could be extrapolated to 
patients under general anaesthesia since autoregulation is lost. One shortcoming with the NIRS 
technique is the sole measurement of rSO2 of the superficial brain cortex, thus ischemia in 
deeper brain structures could be missed. On the other hand our results do not show any short-
coming of NIRS compared to stump pressure in this respect. Several different NIRS devices 
are available commercially, all employing similar technology, but differ in a number of proper-
ties. Accordingly, alternative devices will probably show variability in different optimal cut-off 
values. Only a small number of patients developed neurological symptoms during clamping, 
which makes our results uncertain, and there is a need for larger studies to confirm our results. 
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5.2 Methodological considerations
Random errors cause imprecise results whereas systematic errors affect the validity and lead 
to wrong conclusions.
Bias is a process at any stage of inference that produces results that systematically deviates 
from the true values. 
Bias and errors may have, to some extent, affected our studies.
5.2.1 Selection bias
If the association between exposure and outcome differs between the subjects in a study and 
subjects not in the study, the study population, fails to represent the population for which the 
study is intended to target, there is a selection bias.
In study I, there is an obvious risk for selection bias. In a high volume centre with more expe-
rienced personnel, the experience of choosing cases suitable for CAS (with less risk for com-
plications) is obviously higher as compared to in less experienced centres.
In study III, the indication for choosing treatment with CAS or CEA is lacking. Previous radia-
tion therapy could be associated with poorer outcome and risk of restenosis and could have 
been selected for CAS therapy.
In study IV, only 2.2% of the patients had an occlusion of the contralateral carotid artery, most 
likely a selection bias, since these patients are reported to be at a higher risk for the need of a 
shunt. Patients with larger infarcts on CT scan might have been operated under general anaes-
thesia with a routine shunt. Patients with severe neurologic symptoms could have problems 
to understand study information and thus not be able to give informed consent. This selection 
would probably not affect the internal validity of the test but may affect the external validity 
(generalizability) of the test. 
5.2.2 Information bias
Information bias occurs when the study variables are falsely measured or the data is badly 
collected. Misclassification is a common information bias measurement error, which in turn 
is divided into differential and non-differential misclassification. Differential misclassification 
is when the misclassification in the compared groups differs, which could bias the estimate. 
In non-differential misclassification, the proportion of data with error is the same between the 
groups that are compared, and the results would not be biased but could be hidden or diluted.
Outcome after carotid surgery that is reported by the surgeon who performed the operation 
tends to be better than if follow-up is performed by someone without any relation to the sur-
geon.193 
In study II, we measured the time from qualifying event to operation to see whether it is safe 
to perform CAS early after neurologic symptoms. The date for the qualifying event or alarm 
symptom is defined as the date the patient had the neurological event for which he/she sought 
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medical advice, and not the latest neurologic event. More informative for this type of study 
would have been time from latest event to CAS but this information was not registered in 
Swedvasc earlier.
In study III, we cannot rule out the possibility that some patients could have had a stroke at 
home or in an institution, not being admitted to a hospital. If so, the number would probably be 
low and not related to treatment (i.e. non-differential misclassification).
In study IV, there were instructions for how to measure stump pressure, but in some case 
there might have been an error in the measurements (e.g. clamp might not occlude the artery 
properly). Also, the NIRS technique solely measures rSO2 in the superficial brain cortex, and 
ischemia in deeper brain structures could be missed. 
5.2.3 Confounding
Factors that causes mixing of effects and that are associated with both exposure and outcome 
and not in the causal pathway are called confounding factors. 
In study I, risk factor profile between patients treated with CAS at Södersjukhuset and else-
where in Sweden differed. The sample size of CAS at Södersjukhuset was relatively small, and 
we were not able to adjust for these confounders. 
In study III we adjusted for most of the known confounders. Although the two groups were 
closely matched with similar comorbidities, and the fact that we adjusted for confounders, 
there might still be some unmeasured hidden variables and thus residual confounding.
5.2.4 Precision
A type I error is an incorrect rejection of the null hypothesis; a type II error is incorrectly ac-
cepting the null hypothesis.
In study I, the low number of complications makes it difficult to exclude that the differences 
between CAS in Södersjukhuset and those reported in Swedvasc for stroke or death were due 
to chance alone, and thus the interpretation of the result could be a type I error. 
In study II, only 13 patients were intervened upon within 48 hours, and 85 patients within 3-7 
days. These small numbers limits the report, and a type II error cannot be excluded. 
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6 conclusions
ü	Carotid artery stenting is not as safe as carotid endarterectomy from a national perspec-
tive. Nevertheless, our data shows that it is possible to achieve acceptable results in a 
consecutive selective case series. 
ü	Carotid artery stenting performed within 1 week after onset of a neurologic event is not 
associated with an additional risk of suffering from a perioperative complication as com-
pared with those treated subsequently. 
ü	Carotid artery stenting has an increased long-term risk of stroke and death as compared 
to carotid endarterectomy. This increased risk is mainly explained by an increased rate 
of ipsilateral stroke following the peri-procedural period indicating that carotid artery 
stenting is not as durable as carotid endarterectomy for the long-term treatment of carotid 
artery stenosis.
ü	Near-infrared spectroscopy is a highly sensitive monitoring tool with acceptable speci-
ficity in predicting cerebral ischemia and the need for shunting during carotid endarter-
ectomy, and clearly superior to stump pressure. 
66
Magnus Jonsson
67
7 future PersPectives
Even though few surgical procedures are as examined as treatment for carotid stenosis, there 
are several areas in which further research can lead to improvements for patients with symp-
tomatic and asymptomatic carotid artery stenosis:
Could development of CAS technology such as new embolic protection devices and stents 
(e.g. biodegradable stents covered with ultrathin membrane) and CAS technique (e.g. direct 
puncture of the CCA) lead to improvement of the perioperative results and long-term efficacy 
and even out the gap between CAS and CEA? 
What is best treatment for asymptomatic carotid stenosis and what subgroup will benefit from 
intervention? 
When is “optimal timing” for carotid intervention, and how soon after neurologic event should 
CEA/CAS be performed?
Will general health improvement and future advances in medical therapy require that the RCTs 
for symptomatic stenosis will be repeated?
Will future NIRS, after technical improvement, be the method of choice for selective shunting 
in CEA under general anaesthesia?
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